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ABSTRACT

HARNESSING THE POWER OF TRAINED IMMUNITY IN THE SETTING OF
PANCREATIC CANCER: A NOVEL MECHANISM OF IMMUNE TRAFFICKING
AND TUMOR CONTROL
Anne E. Geller
April 5, 2021

Despite the success of immunotherapy in many types of cancer, pancreatic adenocarcinoma
(PDAC) has yet to benefit. Innate immune cells are critical to antitumor
immunosurveillance and recent studies have revealed that these populations possess a form
of memory, termed trained innate immunity, which occurs through transcriptomic,
epigenetic, and metabolic reprograming. Though trained innate immunity has mostly been
investigated in the context of infection, the induction of trained innate immunity could also
protect against tumors, and specifically pancreatic tumors. Here, we demonstrate that
yeast-derived particulate β-glucan, a known inducer of trained immunity, traffics to the
pancreas following IP administration. This causes a CCR2-dependent influx of newly
characterized monocytes/macrophages to the pancreas which display features of trained
immunity. These trained cells can be activated upon exposure to tumor cells and tumor-
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derived factors, and show enhanced phagocytosis and ROS-mediated cytotoxicity against
pancreatic tumors. In orthotopic models of pancreatic cancer, mice trained with β-glucan
show reduced tumor burden and prolonged survival which is further enhanced when
combined with anti-PD-L1 immunotherapy. Cumulatively, these findings not only add
novel characterization to the dynamic mechanisms, scope and localization of peripheral
trained immunity, but also identify a direct application of trained immunity to cancer that
can be utilized directly within the pancreas to reprogram the immunologically cold tumor
microenvironment of PDAC.
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INTRODUCTION
The diagnosis of pancreatic ductal adenocarcinoma (PDAC) is a devastating one, with
only 10% of patients surviving past 5 years [1]. Although the survival rate since 2014 has
increased from 6% to 10%, pancreatic cancer remains refractory to the majority of
currently available therapeutics. In addition, as the demographics of the United States shift,
it is projected that pancreatic cancer will become the second leading cause of cancer-related
mortality by 2030 and thus presents a significant future challenge for clinicians [2].
Pancreatic cancer is particularly lethal due to the fact that in early stages there are seldom
clinical symptoms, which results in 75-80% of patients being diagnosed with advanced,
non-resectable disease [3, 4]. Even in patients who are eligible for resection, the 5 year
survival rate is only 20-25% [4].

Furthermore, pancreatic cancer has shown little

responsiveness to immunotherapies which have shown remarkable effects in other solid
tumors [5-8]. The Phase I and II clinical trials using CTLA-4 and PD-1 inhibitors both
alone and in combination have been deemed ineffective for the treatment of PDAC, which
is likely explained by the non-immunogenic nature of PDAC [9-11].
A major challenge to the successful application of immunotherapy in PDAC is
overcoming the immunosuppressive pancreatic tumor microenvironment (TME). PDAC is
characterized by a dense pro-tumorigenic desmoplastic stroma, an abundance of
immunosuppressive cell subsets within this stroma such as tumor-associated macrophages
(TAMs), regulatory T-cells (T-regs), and myeloid-derived suppressor cells (MDSCs), a
dearth of activated anti-tumor immune cells, and hypo-vascularity that lends to a hypoxic
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microenvironment [12-14].

Together these conditions make it exceptionally

challenging to effectively deliver immunotherapies to the pancreas and for these
therapeutics to successfully activate anti-tumor immune responses if they do arrive there.
Therefore, novel therapeutics are needed that can not only specifically target the pancreas,
but that can also infiltrate the dense desmoplastic stroma and that are capable of inciting
robust anti-tumor immune responses despite the immunosuppressive TME.
-glucans are a group of biologically active polymers of glucose that are found in the
cell wall of bacteria, fungi, edible mushrooms, yeast, barley, oats, wheat and rye [15, 16].
Though -glucan can come in many forms, only molecules with a (1,3)-linked D-glucose
backbone can act as a biological response modifier (BRM) [17]. Yeast-derived -glucan is
one such example of a BRM, and is made of a linear backbone of (1,3)-linked D-glucose
molecules with (1,6) side chains of variable length [18]. This form of -glucan has been
extensively studied for its ability to reprogram immunosuppressive M2 macrophages into
activated, anti-tumor M1 macrophages [19]. More recently however, -glucan has also
been identified as an inducer of a program of innate immune memory, termed trained innate
immunity [20]. Trained immunity is the concept that when innate immune cells are exposed
to specific initial stimuli, such as -glucan or the Bacillus Calmette-Guérin (BCG) vaccine,
they will undergo metabolic, epigenetic and transcriptomic reprogramming [21-23]. Due
to this reprogramming, when these cells then come into contact with a secondary,
heterologous stimulus, the cell will exhibit enhanced reactivity by means of increased
cytokine production [24, 25].
In this study, we characterize a novel trafficking mechanism of yeast-derived
particulate -glucan which when injected IP traffics in large proportion to the pancreas.
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This results in an influx of trained innate immune cells with an activated phenotype into
the pancreas that notably do not cause pancreatic destruction or signs of pancreatitis. We
show that these trained innate immune cells have antitumor effects, which results in
significant tumor control with prolonged survival in orthotopic pancreatic tumor models.
Given the failure of the majority of immunotherapies alone and in combination to treat
PDAC and the difficulty of targeting these therapeutics to the pancreas, these findings
provide a potential breakthrough in not only targeting the pancreas with an immunotherapy,
but also in recruiting anti-tumor, pro-inflammatory immune cells to the PDAC TME.

Myeloid Cells in the Tumor Microenvironment
There are two arms of the immune system: the innate and the adaptive. Of the two, the
innate immune system is the most evolutionarily conserved arm, and generates rapid, nonspecific inflammatory responses due to signaling by Pattern Recognition Receptors (PRRs)
such as Toll Like Receptors (TLRs). Pathogen Associated Molecular Patterns (PAMPs),
which are conserved molecular motifs of pathogens such as bacteria, viruses, and fungi can
bind to PRRs which will induce innate immune cell activation [26]. Prototypical examples
of PAMPs include bacterial lipopolysaccharides (LPSs) and endotoxins expressed on the
cell membrane of gram-negative bacteria. Engagement of PRRs by PAMPs initiates
intracellular signaling cascades which result in the production of diverse pro-inflammatory
molecules. This response not only targets the invading pathogen, but also is requisite for
the activation and recruitment of adaptive immune responses [27]. The innate immune
system includes macrophages, Dendritic Cells (DCs), Natural Killer (NK) cells, mast cells,
neutrophils, eosinophils, basophils, innate lymphoid cells (ILCs) and proteins of the
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complement cascade. Importantly, while the innate immune system may have
evolutionarily evolved to detect foreign invaders such as bacteria and fungi, these pathways
also participate in the detection of tumor cells [28].
Adaptive immune responses often steal the spotlight with regards to anti-tumor
immunity, and new therapies that promote antitumor immunity have focused primarily on
enhancing adaptive immune responses. For example immune checkpoint inhibitors such as
anti-Programmed cell Death 1(PD-1) monoclonal antibodies (mAbs) which focus on
activating T-cells in the tumor microenvironment (TME) and chimeric antigen receptor
(CAR) T-cell infusions have been two of the most studied recent innovations in cancer
research [29-31]. Despite this focus on adaptive immune responses, it is important to
remember that the activation status of T-cells is not autonomous, but instead closely
controlled by innate immune cells within the TME. The importance of T-cells in antitumor
immunity have been demonstrated by a positive correlation between tumor infiltrating Tcells and prognosis in several cancer types [32-34]. However, in order to generate antigenspecific T-cells and to initiate T-cell responses, Antigen Presenting Cells (APCs) such as
DCs and macrophages are required. In this way, though adaptive cells may exert significant
anti-tumor functions, these effects are dependent on the control and signaling of innate
immune cells. Though there are many innate immune cell types that play an important role
in the pathogenesis of tumors, here macrophages and monocytes will be discussed in detail
as these are the innate immune cells that were investigated in relation to trained immunity
in this project.
In the context of tumors, three important macrophage/monocyte derivates are tumor
associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), and resident
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macrophages [35]. TAMs and MDSCs differentiate from immature peripheral blood
monocytes which originate from common myeloid progenitors (CMPs) in the bone
marrow. In the case of MDSCs, the TME will often secrete growth factors, chemokines
and cytokines that promote the accumulation of immature myeloid cells that upon arrival
to the TME fail to properly differentiate and proliferate [36]. Circulating monocytes can
also migrate to different tissues and are capable of replenishing the populations of resident
tissue-specific macrophages such as Kupffer cells in the liver and alveolar macrophages in
the lung [37]. Additionally, there are unique subsets of resident macrophages, such as glial
cells in the brain, that differentiate from the yolk-sac of a developing embryo and which
are maintained through local proliferation [38]. Within the tumor microenvironment,
macrophages of all origins take on a wide array of phenotypes according to factors within
the TME. Often however, macrophages in the TME take on pro-tumorigenic roles by
promoting angiogenesis, immunosuppression, tumor cell invasion and metastasis [39].
TAMs are often the most abundant population of tumor infiltrating immune cells
within the TME, and have been associated with a more malignant phenotype and a poor
prognosis in various tumor subtypes [40-44]. Macrophages are typically thought to exist in
two polarized states, classically activated (M1) and alternatively activated (M2), though
realistically the status of macrophages is likely not binary and exists on a sliding spectrum
between the two activation states. TAMs often exhibit an alternatively activated, M2,
phenotype where they not only produce anti-inflammatory cytokines such as IL-10, IL-13,
and TGF-, but also can secrete growth factors such as vascular epithelial growth factor
(VEGF) and adrenomedullin to directly support angiogenesis [35, 45-47]. These
immunosuppressive chemokines, cytokines, and enzymes culminate in the direct inhibition

5

of CD8+ and CD4+ effector functions and stimulate the recruitment of regulatory T cells
(Tregs) which further promotes tumor growth [48]. Through the production of matrix
metalloproteinases, serine proteases, and cathepsins, TAMs also modify cell-cell junction
and disrupt the basal membrane which results in increased capability of tumor cells to
invade the primary tumor site and also migrate to distant places to form metastases [4951]. Finally, TAMs are also involved in resistance to chemotherapy and radiotherapy
treatment, which are two of the most heavily utilized treatment modalities in cancer [5255].
MDSCs are a heterogenous group of immature myeloid cells that are not typically
found in healthy individuals and which are divided into two groups: polymorphonuclear
(PMN-MDSCs) and monocytic (M-MDSC). M-MDSCs are mononuclear and express high
levels of Ly6C, a prototypical marker for monocytes, and have very low expression of
Ly6G, a prototypical marker of neutrophils. PMN-MDSCs on the other hand have a multilobular nucleus, similar to a neutrophil, and have high expression of Ly6G and low
expression of Ly6C [56]. In chronic inflammatory states such as cancer, pro-inflammatory
cytokines such as PGE2, M-CSF, G-CSF, GM-CSF, TNF-𝛼, CXCL12, CCL2 and TGF-𝛽
are released locally by immune cells, stromal cells and tumor cells, which can impact
myelopoiesis in the bone marrow and skew the differentiation of immature myeloid cells
recruited to the TME and halt their ability to differentiate [57-60]. These immature myeloid
cells take on potent anti-inflammatory phenotypes once they arrive at the TME and are
known to significantly impair CD4+ and CD8+ T-cell functions, induce NK cell
dysfunction, prevent DC maturation and induce Tregs [61-66]. Due to these varied
immunosuppressive functions, the presence and number of MDSCs in tumors have been
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associated with a shorter overall survival and shorter progression-free survival after
treatment [67-69].
Splenic red-pulp macrophages, lung alveolar macrophages, brain microglia,
epidermal Langerhans

cells, large peritoneal macrophages, F4/80hi pancreatic

macrophages, and cardiac macrophages are all examples of tissue-resident macrophages
that are known to develop in the yolk sac of embryos independently of hematopoietic stem
cells (HSCs) and persist in adult tissues [70-73]. Many of these tissue-resident macrophage
populations are maintained through local proliferation within the tissue, though BMderived circulating monocytes can also migrate to tissues and contribute to the tissue
resident pool of macrophages [74-76]. Like TAMs recruited from the periphery, resident
macrophages present within the TME also play a role in tumor pathogenesis, though their
function has not been as well defined as other macrophage populations. For example,
tissue-resident interstitial macrophages in the lungs of mice were found to significantly
contribute to the pool of tumor-associated macrophages along with the CCR2-dependent
recruited macrophages. Additionally, these resident macrophages were found to associate
with increased tumor growth [77]. Resident macrophages found within the omentum have
been found to be involved in the metastatic spread of ovarian cancer, and in models of
PDAC, tissue resident embryonic derived macrophages were also shown to promote
fibrosis and tumor progression [78, 79]. Even in the brain, resident microglia can exhibit
anti-tumor functions, however they can also be polarized into immunosuppressive tumorsupporting cells by specific tumor-derived soluble factors which cause them to contribute
to tumor angiogenesis, metastasis, dormancy and relapse [80-83]. It has been observed
that resident macrophages pathogenically contribute to the creation of a premetastatic niche
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in organs that are targets of metastasis formation. For example, in a model of metastatic
pancreatic cancer, it was found that liver-resident macrophages, Kupffer cells, uptake
cancer-derived exosomes released from the primary tumor which causes them to secrete
TGF-𝛽 which activates hepatic stellate cells to transform into myofibroblasts that produce
fibronectin and recruit immune cells to the liver [84, 85]. Accordingly, it is important to
distinguish between infiltrating macrophages/ circulating monocyte-derived macrophages
and resident macrophages in order to fully understand the role of TAMs and to develop
therapeutics that can effectively target pro-tumorigenic populations.

The Tumor Microenvironment of Pancreatic Cancer
PDAC accounts for more than 90% of all pancreatic cancer cases, and is also
considered to be one of the most aggressive forms of cancer [86]. The long-term clinical
outcomes of pancreatic cancer are dismal, with the median survival from time of diagnosis
being 3-6 months in patients who do not receive treatment, and 23 months in patients who
receive resectional surgery and adjuvant therapy [87]. One reason that pancreatic cancer
is so deadly is that it is often diagnosed at a late stage of cancer progression, as patients
often only begin showing non-specific symptoms of the malignancy once it has grown
large enough to press on the bile duct, resulting in symptoms of jaundice, weight loss and
anorexia. Pancreatic cancer has a propensity for vascular invasion, rapid and robust
lymphatic spread, and perineural invasion, meaning that tumor cells surround nerves which
allows for an alternative route for metastatic spread and results in considerable pain [88].
To date, most oncological interventions have failed to produce benefits in long-term
survival and resection remains one of the most effective modalities. Unfortunately, a mere
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10-20% of patients with primary tumors in the head of the pancreas, and less than 3% of
patients with a primary tumor in the head or tail of the pancreas are candidates for resection
[89-91]. The primary goal of surgical resection is to achieve a negative resection margin
(R0), however despite this, most patients will develop a recurrence at some point following
surgical resection [92]. Most patients diagnosed with PDAC will go on to receive some
form of adjuvant chemotherapy. FOLFIRINOX, which is a chemotherapy regimen
consisting of Leucovorin, 5-fluotouracil, irinotecan and oxaliplatin, is currently the
standard adjuvant therapy used and has led to relatively improved outcomes for patients
with PDAC, however are not sufficient for patients with advanced disease [93, 94].
Another particular challenge of PDAC is the high degree of genetic heterogeneity that
occurs not only between patients but within a single primary tumor [86]. Whereas in lung
cancer or melanoma where specific genetic mutations, such as EGFR and BRAF,
respectively, provide excellent targets for interventional therapies, within a single PDAC
tumor there exist a plethora of mutations that are not shared between patients [95].
Additionally, the use of immunotherapy, such as immune checkpoint mAbs anti-CTLA-4,
anti-PD-1 and anti-PD-L1 have not shown meaningful clinical efficacy and are currently
not approved for use in patients with pancreatic cancer[6, 96].
An important reason that PDAC shows such resistance to commonly used adjuvant
therapies such as chemotherapy and immunotherapy is the immunosuppressive TME. One
hallmark of the PDAC TME that is present in both the primary tumor and sites of distant
metastases is the formation of a dense desmoplastic stroma around the tumor [97].
Pancreatic stellate cells are activated by tumor-secreted factors which causes these
myofibroblast-like cells to initiate pro-fibrotic mechanisms. This fibrotic desmoplastic
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layer around the tumor creates a physical barrier around tumors that limits immune cell
invasion, promotes tumor angiogenesis and prevents the delivery of systemically delivered
therapeutics such as chemotherapy and immunotherapy from arriving at the tumor site [98,
99]. Importantly, PDAC has also been classified as an immunologically “cold” tumor
meaning that there are few activated anti-tumor T-cells and many immunosuppressive
Tregs, TAMs and MDSCs. In PDAC, an increased number of Tregs, MDSCs and TAMs
have all has been associated with promoting PDAC and decreased overall survival [98,
100-102].
The dense desmoplastic stroma that decreases the formation of normal vasculature
also creates a hypoxic environment that effectively recruits immunosuppressive MDSCs
and assists in their differentiation upon arrival to the tumor site [103]. Patients with PDAC
exhibit elevated levels of systemic and intra-tumoral MDSCs upon progression of disease,
and within the TME MDSCs are known to directly suppress the formation of antigenspecific T-cells and induce Tregs [104-106]. Upon migration to the tumor site, MDSCs
have also been shown to differentiate into TAMs, though in murine models of pancreatic
cancer, 50% of TAMs were also shown to derive from resident macrophage populations
[78, 107]. Accordingly, analysis of patient’s PDAC samples show that TAMs exhibit M2
markers such as CD206 and CD163 and secrete high levels of IL-10. An increased number
of M2 macrophages is associated with larger tumor size, early recurrence in the liver, local
recurrence and shorted survival in patients [108]. TAMs have been specifically shown to
mediate gemcitabine resistance in PDAC by upregulating cytidine deaminase (CDA)
which is the enzyme responsible for metabolizing gemcitabine after its transport into the
cell, thereby expediting its inactivation [109]. TAMs also have been shown to suppress
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clinical responses to irradiation and angiogenic inhibitors that are commonly used in
pancreatic cancer [110].
Due to the pronounced presence of MDSCs and TAMs within the PDAC TME
combined with their ability to modulate the function of many other immune cell types,
myeloid cells within the TME have become the popular target for new anti-cancer
therapeutics.

Accordingly, it has been shown that depleting tumor-infiltrating

macrophages

can

improve

chemotherapeutic

responses

and

can

relieve

immunosuppression [111]. Further, while it has been shown that checkpoint inhibitor
therapies such as anti-CTLA-4 or anti-PD-L1 as a monotherapy are not effective in
pancreatic cancer, the depletion of TAMs using CSF-1 inhibition synergized with
checkpoint immunotherapy in PDAC [112]. This provides a convincing rationale to
develop therapeutics with the goal of reprograming immunosuppressive TAMs and
MDSCs within the TME in order to unleash the potential of immunotherapy in the setting
of PDAC.

Trained Innate Immunity
Given the critical role that innate immune cells play in the TME of PDAC, we now turn
our attention to a program of innate immune cell memory, called trained immunity,
which we propose has the potential to reprogram immunosuppressive myeloid cells
within the TME.

Throughout evolution, the vast majority of cellular life has existed without the
protection from adaptive immune responses. Adaptive immunity is actually a relatively
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contemporary evolutionary adaptation, where until the emergence of jawed fish 500
million years ago, multicellular organisms existed only with features of innate immunity
[113, 114]. In the absence of protective memory features of adaptive immunity, plants,
protists, invertebrates and lower animals evolved ways to protect themselves from
recurrent infections through the development of systemic acquired resistance (SAR). SAR
is a program of non-specific protection that is responsible for the observation that following
inoculation with attenuated organisms, plants are protected from subsequent infections
from several infectious agents such as fungi, viruses and bacterial pathogens [20, 115].
Though ancient, the ability to mount memory-like innate immune responses certainly
conferred an evolutionary advantage, and this capability was thus retained as evolution
progressed towards higher vertebrates. These mechanisms underpin the recent discovery
of trained innate immunity, which posits that mammalian innate immune cells exhibit
immunological memory of previous pathogen interactions which allows them to better
respond to and defend against future infections, even from different sources.
The concept of trained immunity in humans has been present for almost a century.
In 1931, a Swedish study showed that infants given the Bacille Calmette-Guérin (BCG)
vaccine against Mycobacterium tuberculosis (TB) exhibited increased survival rates as
compared to infants that did not receive the BCG vaccine, which could not be only due to
having immunity to TB [116]. Accordingly, epidemiologists were the first to truly
characterize trained immunity, where it was noted that recipients of the smallpox vaccine
were not only protected against smallpox but also other infections such as measles, scarlet
fever and syphilis [117]. In the late 1900s, a number of additional studies came out which
further characterized trained immunity, where it was shown that exposure to glucans, fungi
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and other vaccines, such as the measles vaccine, afforded non-specific protection from later
heterologous infections [118-122].
A 2012 study by Quintin et al, more formally confirmed the phenomenon of innate
immune memory by showing that mice exposed to a low dose of C. albicans induced
protection against reinfection with C. albicans in Rag-1 deficient mice which lack B and
T-cells. Further, they showed that the protection to C. albicans was driven by macrophages
and monocytes, which produced increased levels of TNF-, IL-6, and IL-1 and showed
an increased phagocytic capacity [123]. Importantly, they also showed that a specific
component within the cell wall of C. albicans, -1,3-(D)-glucan (-glucan), was
responsible for initiating these effects. Since then, a great deal of investigation has been
performed to understand the mechanisms of trained immunity involving -glucan. Human
and animal studies alike have shown that exposure to -glucan protects from secondary
infections such as Staphylococcus aureus, TB, Leishmania braziliensis and influenza
[124-126]. Together, these studies support that -glucan is a potent inducer of trained
immunity such that when innate immune cells that have been exposed to -glucan are
exposed to heterologous secondary stimuli of many different etiologies, they will mount a
qualitatively different, and quantitatively stronger response than cells that are untrained
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[127]. In experiments involving trained immunity, LPS is often used as a secondary
stimulus, and it is capable of clearly re-stimulating trained cells (Figure I.1).
Figure I.1: Schematic of trained immunity
Cells are exposed to an initial training stimulus such as -glucan after which they undergo
epigenetic, metabolic and mitochondrial reprogramming. When cells are then exposed to

a secondary stimulus, such as LPS, cells then exhibited responses that are more robust
than the initial stimulus or the secondary stimulus alone. In effect, the initial stimulus
causes cells to have a more vigorous response to a secondary stimulus.

Trained innate immunity primarily involves the training of macrophages and
monocytes, though DCs, Natural Killer (NK) cells and neutrophils have been shown to be
involved in trained immunity [128-130]. Following induction, it has been observed that
trained immunity can last from weeks to months. Given that monocytes in the periphery
are typically short lived, this brought into question whether cells in the periphery are
directly trained or whether training agents may impact the BM thus leading to more lasting
effects. Additionally, because cells in the periphery are often terminally differentiated and
therefore unable to give rise to a cohort of trained progeny, it was hypothesized that trained
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immunity may directly impact the HSCs in the BM which then gives rise to trained cells
systemically. Fittingly, mice injected with intraperitoneal (IP) -glucan show a biased
expansion of Lin-Sca1+cKit+ (LSKs) and Multipotent Myeloid Progenitors (MMPs) in the
BM [131]. Under the current paradigm of trained immunity, the education of HSCs and
the induction of myelopoiesis in the BM is responsible for the generation of “central”
memory which then creates a repertoire of innate cells possessing innate immune memory
features, which then migrate to the peripheral tissues to generate peripheral memory [132,
133].
In myeloid cells, loci encoding inflammatory signaling are often in a repressed
configuration, which is due to low levels of acetylation of histones and minimal RNA
polymerase II present on enhancer and promoter regions [134, 135]. Following exposure
to inducers of trained immunity, drastic changes to the accessibility of DNA take place
through the acetylation of histones and the recruitment of RNA polymerase II, and result
in the activation and upregulation of gene expression that can be on the order of 100 times
higher than baselines levels. These changes are also driven by stimulation-responsive
transcription factors such as NF-κB and STAT proteins being recruited to gene promoters,
which then recruit co-activators such as histone acetyltransferases and chromatin
remodelers. Together, these significantly increase the accessibility of chromatin, which
allows for better accessibility of proteins involved in transcription, and ultimately more
robust responses upon restimulation [127, 136-138]. While inducers of trained immunity
generally work by increasing the activation status of innate immune cells through these
described epigenetic modifications, the exact mechanisms can be different among initial
stimuli [139].
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Dectin-1 is the main receptor for -glucan, and accordingly it was shown that invitro models of trained immunity using -glucan are mediated by dectin-1 signaling [140].
Stimulation of myeloid cells with β-glucan has been shown to directly recruit and activate
SyK kinase through dectin-1 followed by recruitment of Card9 to form the
Card9/Bcl10/Malt-1 complex that activates the IκB kinase complex resulting in the
activation of key transcription factor NF-κB. Activation of NF-κB is then able to initiate a
pro-inflammatory signaling cascade [141-143]. While the specific molecular mechanisms
of trained immunity are still being investigated, mounting evidence shows that following
dectin-1 activation, transcriptomic, epigenetic, metabolic, and mitochondrial alterations
take place which each plays an integral role in the initiation and expression of trained
immunity.
Activation of the Dectin-1 receptor by β-glucan has been shown to directly cause
important changes to the epigenetic status of immune gene promoters. An example of the
epigenetic priming induced by β-glucan is that upon Dectin-1 activation, nuclear factor of
activated T-cells (NFAT-1) is dephosphorylated, which results in its translocation through
the nuclear membrane. NFAT-1 mediates β-glucan-driven epigenetic training by
upregulating immune gene-priming long non-coding RNAs (IP-incRNAs) which
culminates in increased levels of trimethylation of histone H3 at lysine 4 (H3K4me3) at
promoter sites [123, 144]. High levels of H3K4me3 are associated with robust levels of
gene expression, and so this epigenetic effect results in more vigorous cytokine production
upon re-stimulation of β-glucan-primed immune cells [145]. Such epigenetic modifications
driven by β-glucan result in inflammatory genes that are ideally positioned to be rapidly
activated by secondary infections or stimuli, such as a virus, bacteria or even a tumor cell.
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This explains why myeloid cells trained with β-glucan release increased levels of TNF-,
IL-6, and IL-1 following restimulation with LPS.
Metabolic changes are also a prominent feature of β-glucan induced trained
immunity, as vital energy metabolites regulate chromatin-modifying epigenetic enzymes,
methylation, histone modification, and the position of the nucleosome by acting as
substrates and co-factors. Consequently, the energy state of a cell and the metabolic
programs that are initiated as a result of β-glucan stimulation tightly modulate the
transcription of immunogenic genes [146]. The metabolic switch from oxidative
phosphorylation toward aerobic glycolysis is a key feature of trained immunity, which has
been shown to be mediated through the AKT/mTOR/HIF1α pathway [21]. Other notable
metabolic features of trained immunity are a decrease in itaconate, a product of the
decarboxylation of cis-aconitate, and increased fumarate and mevalonate accumulation
through upregulation of the TCA cycle following stimulation with LPS. β-glucan signaling
notably inhibits the LPS mediated upregulation of immune-responsive gene-1 (IRG-1), the
enzyme that is responsible for itaconate generation, and stimulates the activity of succinate
dehydrogenase, leading to increased fumarate production [147]. This is critically important
as itaconate is known to induce immune tolerance and anti-inflammatory properties in
human monocytes.
To date, mechanisms of trained immunity have been primarily studied with regards
to infection. Recently however, two studies have highlighted that it may also be possible
to utilize the induction of trained immunity to kill cancer cells. One of these studies by
Kalafati et al., describes that pre-treatment of mice with β-glucan induces long-term
transcriptomic and epigenetic rewiring of granulopoiesis which results in the creation of
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neutrophils that have an anti-tumor phenotype [130]. In the same issue of Cell, another
paper regarding the use of trained immunity in the setting of cancer appeared, though in
this paper the authors utilized a novel nano-biologic therapeutic called MTP-HDL.
Following injection, MTP-HDL was found to target and accumulate in the hematopoietic
organs of mice and non-human primates. In the BM specifically, MTP-HDL was shown to
initiate epigenetic modifications in MPPs that are consistent with the initiation of trained
immunity. For example, they showed that MPPs had higher chromatin accessibility near
the promoters of genes that regulate TNF-𝛼 and IL-6. During myelopoiesis, these trained
myeloid cells were able to initiate anti-tumor effects in a B16F10 subcutaneous model of
melanoma and not only showed inhibition of tumor growth, but to also showed the
capability to potentiate the function of immune checkpoint inhibitor therapy [148, 149].
These two recent articles are the first descriptions of the use of β-glucan-induced
trained immunity in the setting of cancer, however both studies utilized subcutaneous
models of tumors, which do not fully encapsulate the organ-specific features of
immunosuppression that are present in tumors. Studies over the last three decades have
consistently shown that the use of subcutaneous tumor models rarely result in the
occurrence of metastatic disease, and they never result in metastatic disease in the clinically
relevant organs according to the type of tumor cell used [150-152]. For example pancreatic
cancer often metastasizes to the liver and lung, however a subcutaneous model of
pancreatic cancer would not result in metastases to these organs. Additionally, the
recruitment of anti-tumor immune cells is highly dependent on the vasculature both outside
and within a tumor, which are controlled by angiogenic processes at the tumor site. There
is evidence that tumor vascularity is organ-site specific and therefore subcutaneous models
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of cancer fail to fully recapitulate the true vascular environment of a tumor [153].
Additionally, in the setting of pancreatic cancer, for example, pancreatic stellate and
stromal cells play a critical role in tumor progression, as do resident macrophages Kupffer
cells in the setting of hepatocellular carcinoma. Subcutaneous models fail to take into
account these organ-specific drivers of immune-evasion, which can lead to overly
extrapolated or interpreted conclusions about the efficacy of anti-tumor therapeutics [154].
Overall, the use of subcutaneous models of cancer leads to shortcomings in the
understanding of blood flow, intravascular-tumor cell trafficking, extravasation of tumor
cells, the architecture of the TME, and the distribution and targeting efficacy of cellular
and chemical therapeutics [155, 156]. As such, while these initial studies that investigate
the role of trained immunity in combating cancer are exciting, studies such as the ones
presented in this dissertation are critical to understanding if the anti-tumor mechanisms of
trained immunity are applicable in in situ pre-clinical models of cancer.
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CHAPTER I
THE TRAFFICKING AND BIODISTRIBUTION OF β-GLUCAN

CHAPTER I INTRODUCTION
Even before β-glucan was identified to be involved in initiating trained innate immune
responses, β-glucan has been extensively studied for its immunomodulatory properties.
Understanding the trafficking mechanisms of β-glucan has thus been a focus of β-glucan
related research. Of all of the routes of administration, orally administered β-glucan has
been the most extensively studied, however intravenous (IV) and intraperitoneal (IP)
injections of β-glucan have also been used. Following oral administration, β-glucans move
into the proximal small intestine where they are phagocytosed by intestinal epithelial cells
or pinocytic microfold cells (M-cells) which transport β-glucan from the intestinal lumen
to immune cells within Peyer’s patches [157-159]. Following exposure to β-glucan,
gastrointestinal macrophages then migrate through the bloodstream toward the lymph
system, ultimately resulting in trafficking to the bone marrow, spleen and lymph nodes
[160].
IP injection of β-glucan has been less extensively studied than oral administration,
though there are some studies which show that IP injection has more profound effects on
immunological activity than does oral administration [161]. Importantly, experiments
utilizing β-glucan for the initiation of trained immunity typically use a model of
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intraperitoneal injection. Zheng et al. found that following IP administration, βglucan was ingested by resident peritoneal macrophages which then trafficked to the lymph
nodes, thymus and the tumor site in BALB/c mice bearing subcutaneous H22
hepatocellular carcinomas [162]. Other than this study, there exists sparse detailed
information about where exactly β-glucan traffics to following IP injection. As such, we
first sought to identify where β-glucan traffics to following IP administration. In these
studies we utilize a highly purified form of β-glucan, whole glucan particles (WGP), that
was purified from Saccharomyces cerevisiae.

CHAPTER I RESULTS
To assess the trafficking of particulate -glucan, WGP was tagged with (5-(4,6Dichlorotriazinyl) Aminofluorescein) (DTAF), and injected IP into wild-type (WT)
C57BL/6 mice. Three days following IP administration (3-day WGP), the lung, bone
marrow, spleen, inguinal and mesenteric lymph nodes, peritoneal cavity cells, and pancreas
were harvested to detect the presence of DTAF-WGP. While there was some trafficking of
the DTAF-WGP to the BM, spleen, and mesenteric lymph nodes, and residual DTAF-WGP
in the peritoneal cavity, the pancreas showed a striking and unexpected presence of the
DTAF-WGP (Fig 1.1A). In fact, the pancreas appeared bright yellow upon gross visual
analysis (Fig 1.1B). To further assess this trafficking and to ensure that the DTAF label
was not involved in the trafficking mechanism, WGP was radiolabeled with

89

Zr and

injected IP (Fig 1.2A) or incubated for 2 hours with peritoneal macrophages that were then
injected IP (Fig 1.2B). Mice were first imaged using a PET/CT scan 48 hours following
injection and green circles are used to indicate the observed preferential accumulation of
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the

89

Zr-WGP in the pancreas. A necroscopy was then performed and the radioactive

signature of each organ was measured. In accordance with the flow cytometry data, 89ZrWGP trafficked in large quantities to the pancreas, and was found in lower levels in the
spleen, liver and intestinal system. Peritoneal macrophages that were cultured with 89ZrWGP and then injected IP had similar though slightly more diversified trafficking than the
pure 89Zr-WGP, and also accumulated most prominently in the pancreas (Fig 1.2B).
In an effort to assess the role that the known receptor of WGP played in the trafficking,
mice lacking the C-type lectin receptor, Dectin-1, (Dectin-1-/- mice) were injected with
DTAF-WGP and 48 hours later the pancreases were harvested. As compared to WT mice,
Dectin-1-/- mice showed a 5-fold decrease in the amount of WGP that trafficked to the
pancreas, as assessed by flow cytometry (Fig 1.3A). 89Zr-WGP was also injected IP into
WT mice and Dectin-1-/- mice. As compared to WT animals, there was significantly less
trafficking of WGP to the pancreas of Dectin-1-/- mice (Fig 1.3B). To ensure that this
process was in fact -glucan specific, a polystyrene-based latex 3 μm fluorescent particle,
the same size as a WGP particle, was injected IP and was not found to accumulate in the
pancreas (Fig 1.4). Finally, as it had been observed that WGP that had been phagocytosed
by peritoneal macrophages also trafficked to the pancreas upon IP injection of the WGPloaded peritoneal macrophages, we also wanted to know whether peritoneal macrophages
phagocytosed WGP in vivo. To investigate this, DTAF-WGP was injected into mice IP,
and 4 hours later the peritoneal macrophages were harvested. Confocal microscopy was
performed to assess if peritoneal macrophages phagocytosed IP injected DTAF-WGP (Fig
1.5). This study showed that peritoneal macrophages did phagocytose WGP in vivo, as the
DTAF-WGP could be clearly seen within these cells in the confocal images.
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It appeared form these studies that there was a connection between the peritoneal cavity
contents and the pancreas. To further understand how WGP trafficked from the peritoneum
to the pancreas, peritoneal macrophages were harvested from WT mice and stained with
CFSE. These cells were then adoptively transferred into recipient mice and these mice
received either IP PBS or WGP. Mice that received IP WGP displayed more CFSE+
macrophages trafficking to the pancreas than those that received PBS (Figure 1.6). This
highlights that there exists a baseline flux of macrophages from the peritoneum to the
pancreas that can be utilized and upregulated in the presence of IP WGP.
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CHAPTER I FIGURES
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Figure 1.1: IP DTAF WGP preferentially accumulates in the pancreas
(A) DTAF-WGP was injected I.P. and 3 days later different tissues were harvested and
assessed for the presence of the DTAF-WGP by flow cytometry. (B) Gross anatomical
view of the presence of DTAF-WGP in the pancreas causing it to appear bright yellow.
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Figure 1.2: Analysis of WGP trafficking using radio-labeled 89Zr-WGP
(A) WGP was labeled with 89Zr-WGP or (B) peritoneal macrophages were incubated with
89

Zr-WGP and washed, followed by I.P. injection.

trafficking of the

89

PET/CT imaging displays the

Zr-WGP throughout the body after 48 hours. Following the PET/CT

scan, organs were removed and individually assessed for radioactivity using a gamma
counter. (n=3).
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Figure 1.3: Dectin-1 regulates the trafficking of WGP to the pancreas
(A) Dectin-1-/- mice or WT mice were injected with DTAF-WGP and the accumulation of
DTAF-WGP in the pancreas was assessed by flow cytometry. (n=4) (B) Dectin-1-/- mice or
WT mice were injected with 89Zr-WGP and 48 hours later a PET/CT was used to assess
the amount in the pancreas. The signal was quantified by reporting the % of injected dose
(%ID) in the pancreas. (PBS n=4, WGP n=4) Data are represented as mean ± SEM. *p
<.05, ***p <.001
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Figure 1.4: A polystyrene bead the same size as WGP does not accumulate in the
pancreas.
Fluorescent 3 μm polystyrene beads or PBS were injected IP and 24 hours later the
pancreas was assessed for the presence of a fluorescent signal, indicating trafficking.
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Figure 1.5: Confocal microscopy of in vivo phagocytosis of DTAF-WGP
Mice were injected IP with DTAF-WGP and 4 hours later mice were euthanized, peritoneal
macrophages were harvested, cytospun and analyzed using confocal microscopy.
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Figure 1.6: There is a transient flux of macrophages between the peritoneal cavity
and the pancreas that is utilized to deliver WGP to the pancreas
Peritoneal macrophages were harvested from WT mice and incubated with CFSE. These
cells were then adoptively transferred IP into WT mice. 1 day after transfer of CFSE+
peritoneal macrophages, mice were injected with WGP and 24 hours following the
pancreata were harvested and the presence of CFSE+ macrophages was measured using
flow cytometry. (PBS n=3, WGP n=3) Data are represented as mean ± SEM, **p <.01
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CHAPTER I DISCUSSION
As stated earlier, though the IP administration of β-glucan has been broadly used
for inducing trained immunity, it has not been well established where it traffics to following
injection. These studies identify that WGP traffics in small quantities to the lymph system
and to the bone marrow. It is this trafficking to the bone marrow that likely causes the
effects of central trained immunity. Surprisingly, we found that WGP also trafficked in
large proportions to the pancreas which has not been reported before. It was shown that glucan can traffic directly into the pancreas and can also be phagocytosed by macrophages
which then traffic into the pancreas. While the relationship between the peritoneal cavity
and the pancreas has not been well defined, studies relating to the pathophysiology of acute
pancreatitis (AP) have identified that peritoneal macrophages are a principal contributor
to the inflammatory response in AP [163]. Our imaging data indeed show that peritoneal
macrophages that phagocytose isotope-labeled WGP primarily traffic to the pancreas.
Additionally, in an experiment in which CFSE labeled peritoneal macrophages were
adoptively transferred IP, these macrophages were found at low concentrations in the
pancreas 24 hours later. Studies on liver injury have further supported this model of a
dynamic interchange of cells between the peritoneal cavity and solid organs that is
independent of the circulation [164]. Together this suggests that even in homeostatic
conditions there exists a basal level of immune cell exchange between the pancreas and
peritoneal cavity that can be exploited in the setting of particulate -glucan.

While we had identified that macrophages that had phagocytosed WGP traffic to
the pancreas and carry WGP with it, we also assumed that naked DTAF-WGP may also
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traffic to the pancreas due to the visually yellow appearance of the pancreas. To try and
understand whether peritoneal macrophages were critical in the trafficking of WGP to the
pancreas, we sought to deplete peritoneal macrophages using liposomal clodronate [165].
Despite reports that IP injection of liposomal clodronate results a clean depletion of
peritoneal macrophages, we found that one day following injection, macrophages were not
entirely depleted, and further that the immunological makeup of the peritoneal
compartment was altered to have increased numbers of monocytes and neutrophils. Further
studies are needed to determine if peritoneal macrophages are requisite for WGP
trafficking to the pancreas or if naked WGP may traffic there entirely without the assistance
of them.
While the impact of -glucan on the immune cells of the pancreas will be explored
in future sections of this dissertation, this tropism of -glucan to the pancreas carries
interesting clinical applications given that -glucan has the capability to function as a
delivery vesicle for cancer therapeutics. Glucan particles are hollow, and as a result have
become the subject of research aiming to utilize these properties to employ β-glucan as a
vesicle to encapsulate, transport, deliver and release therapeutics within the TME, and
specifically to macrophages. Several groups have already shown that it is possible to load
β-glucan with different electrostatically-bound compounds, such as siRNA, DNA, protein,
and small molecules in order to deliver these payloads to macrophages and DCs [166-169].
In the setting of pancreatic cancer, where it is not only exceptionally challenging to target
systemic therapies to the pancreas, but it is also imperative to deliver therapeutics that can
reprogram the immunosuppressive TME, this poses an attractive treatment strategy. For
example, in one study researchers developed a glucan-based siRNA carrier system which
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was shown to effectively assemble siRNA into uniformly distributed nanoparticles. On
administration, these β-glucan containing siRNA nanoparticles were shown to reduce gene
expression of migration inhibitory factor (MIF), a cytokine and chemokine known to be
upregulated in the TME in primary macrophages [170]. Upon IV injection, these
nanoparticles were able to mediate a sustained reduction of MIF in tumor associated
macrophages (TAMs) in a mouse model of 4T1 mammary cancer [143, 171]. Together
these studies indicate that this newly characterized trafficking mechanism of β-glucan
could be exploited to deliver therapeutics directly to the PDAC TME, and future studies
are underway to investigate this. Ultimately, these data highlight a previously
uncharacterized, dectin-1 dependent tropism of -glucan to the pancreas that could be
utilized to deliver therapeutics directly to the pancreas in the setting of cancer.
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CHAPTER II
-GLUCAN TRAFFICKING TO THE PANCREAS INCITES AN INFLUX OF
INNATE IMMUNE CELLS THAT SHOW A PHENOTYPE OF TRAINED
IMMUNITY

CHAPTER II INTRODUCTION
Now that we had identified that WGP traffics to the pancreas following IP
administration, we next turned our attention to investigating whether immune changes in
the pancreas occurred as a result of the trafficking. It had previously been shown that IP
administration of WGP causes an expansion of MPPs and LSKs in the bone marrow. We
repeated this analysis to confirm that our specific form of particulate yeast-derived glucan had the same capability to incite central trained immunity. Unsurprisingly, WGP
trained mice showed an expansion of Lin-Sca-1+c-Kit+ (LSKs) and CD48+CD150- (MPPs)
7 days after injection in our model of trained immunity indicating the successful induction
of central trained immunity (Fig 2.1A+B). Additionally, DTAF-WGP was found to traffic
in small proportions to the bone marrow (Fig 2.1C). These results confirmed that the WGP
used in our experiments stimulates a typical program of trained immunity. While this
expansion has been noted before, the presence of trained cells within the pancreas has not
been described before. Thus, the trafficking of WGP to the pancreas also caused us to
question not only how the immune cell populations change, but also whether cells in the
pancreas may also display features of trained immunity.
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CHAPTER II RESULTS
Trafficking of immune cells into the pancreas
After discovering that -glucan displays tropism toward the pancreas, it was also
observed that the immune landscape of the pancreas was significantly altered following
WGP treatment. Arrival of WGP to the pancreas was accompanied by a distinct influx of
CD11b+ myeloid cells to the pancreas by day 3, some of which had phagocytosed WGP
(Fig 2.2A). This finding led us to examine how overall immune populations of the pancreas
are impacted following IP WGP treatment. As it has been previously observed that the
immune changes associated with trained immunity in the BM are most pronounced one
week following exposure to -glucan [131], the immune profile of the pancreas was
examined in mice treated with a 3 m polystyrene microparticle or WGP 7 days following
IP injection. First, it was observed that there was about a 10-fold increase in the overall
percent of CD45+ immune cells in the pancreas after WGP treatment (Fig 2.2B). There
was an observed increase in the absolute number of CD45+ immune cells (Fig 2.2C). A 3
m polystyrene microparticle control did not have such effects (Fig 2.2D), indicating that
this immune cell influx is WGP specific. To further classify which cell types were
responsible for this expansion of the CD45+ immune population, the relative percent (Fig
2.2B) and absolute number (Fig 2.2C) of myeloid cells (CD11b+), T-cells (CD3+), B-cells
(CD19+), and NK cells (NK1.1+) were evaluated. The cumulative changes in the pancreas
are represented by pie charts which demonstrate that the expansion of the myeloid
compartment is responsible for the relative decrease in the percentage of other cell
populations and the overall increase in the CD45+ population following WGP treatment
(Fig 2.2E).
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We next investigated whether this influx of CD11b+ immune cells was transient, so the
percent of overall CD45+ cells and CD11b+ cells in the pancreas following IP injection was
measured at 7,10, 18 and 30 days. While the percent of CD11b+ cells peaked at day 7, the
percent of CD45+ cells appeared to peak at day 10 which may indicate that following influx
of CD11b+ cells to the pancreas, an influx of other immune cell types may follow, though
it was not investigated what type of cells these may be. The percent of immune cells in the
pancreas decreased to basal levels by day 30, demonstrating that this influx is transient (Fig
2.3A). Within the myeloid compartment, we observed that the percent (Fig 2.3B) and
absolute numbers (Fig 2.3C) of macrophages (F4/80+), monocytes (Ly6C+), and
neutrophils (Ly6G+) were all increased. The influx of immune cells into the pancreas was
shown to be dependent on the dose of WGP injected, where higher doses of WGP were
associated with increased influx of overall CD45+CD11b+ myeloid cells and
CD45+CD11b+F4/80+ macrophages (Fig 2.4). We also wanted to ensure that this observed
phenomenon was not specific to C57BL/6 mice, and so investigated whether other
commonly used mouse strains, such as BALB/c mice, also showed an influx of immune
cells into the pancreas following WGP injection. BALb/c mice also showed a 15 fold
increase in CD45+ cells in the pancreas after WGP injection (Figure 2.5).
As pancreatitis and the destruction of pancreatic islets are associated with immune cell
infiltration of the pancreas, H+E of the pancreas was performed to assess the integrity of
pancreatic islets 7 days after WGP administration (Fig 2.6A). Serum amylase, a diagnostic
marker of pancreatitis, was also measured in WGP vs PBS-treated mice 7 days following
injection (Fig 2.6B). Neither the islets nor the serum amylase were adversely impacted by
WGP treatment and the observed immune influx, indicating that the immune cell influx in
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this mechanism does not cause pancreatic destruction. Further, following WGP treatment
mice were monitored for up to 3 months, and no morbidities or mortalities were associated
with WGP treatment.
As the islets were not adversely impacted by the influx of immune cells, we wondered
where the immune cells were located. H+E imaging of PBS and WGP treated mice showed
that the cellular infiltrates appeared to be located in a layer around the pancreas that was
rich in adipose tissue, and were starkly increased in WGP treated mice (Fig 2.7A+B). This
layer was connected to the pancreas and was identified as being a part of the serosa capsule
that surrounds the pancreas.

Trained Immunity in the Pancreas
To investigate whether the cells found to infiltrate the mouse pancreas following WGP
treatment displayed a phenotype of trained immunity, we used a standard training protocol
in which mice were treated with WGP or PBS and 7 days later the pancreas were harvested,
processed into a single cell suspension, and then restimulated with LPS. TNF- production
has been used as a surrogate marker to evaluate the trained response. Overall CD11b+
myeloid cells, CD11b+F4/80+ macrophages and CD11b+Ly6C+ monocytes were all shown
to produce more TNF- due to prior exposure to WGP, as assessed by the percent of TNF+ cells and the MFI (Fig 2.8). To further assess these findings, CD11b+ cells were sorted
from the pancreas of these mice and restimulated ex-vivo with LPS, and the TNF- and IL6 levels in the supernatants were measured by ELISA. As compared to CD11b+ cells from
PBS mice, cells from WGP-trained mice that were restimulated with LPS produced
significantly more TNF- and IL-6 (Fig 2.9A), signifying that WGP treated pancreatic
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CD11b+ cells were trained. These results were further confirmed using RT-PCR, where
pancreatic CD11b+ cells sorted from PBS or WGP-trained mice were shown to produce
more TNF-, IL-6, iNOS and less IL-10 due to WGP treatment (Fig 2.9B). Together these
findings indicate that not only does WGP incite a trained phenotype in the cells that traffic
into the pancreas, but that they also have an overall pro-inflammatory phenotype.
Some reports have indicated that the microbiota of mice can play a role in the induction
of trained immunity [172, 173]. The microbiome of mice can be drastically different
between facilities and breeding colonies, and so we wanted to confirm that the induction
of trained immunity in the pancreas was not dependent on factors related to the microbiome
of the mice in our facility [174-176]. To investigate this, germ-free mice housed in the
germ-free facility at the University of Louisville were injected IP with WGP and the
induction of trained immunity in pancreatic myeloid cells was assessed (Fig 2.10).
Myeloid cells from WGP-treated germ-free mice did display increased production of
TNF as compared to PBS-treated mice, indicating that while the microbiota may play a
role in trained immunity, it was not a critical factor in this model.

RNA-Seq and CyTOF Analysis of WGP-induced influx of myeloid cells
RNA sequencing (RNA-Seq) was then performed on FACS sorted CD45+CD11b+ cells
7 days following PBS or WGP training to obtain an unbiased and comprehensive
characterization of myeloid populations in the pancreas. A total of 1459 Differentially
Expressed Genes (DEGs) were discovered, with 661 upregulated and 798 genes
downregulated in the WGP-trained setting (Fig 2.11A). In accordance with the observed
influx of immune cells, the DEGs related to leukocyte chemotaxis, leukocyte migration
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monocyte chemotaxis, macrophage migration, mononuclear cell migration, and myeloid
leukocyte migration (Fig 2.11B) were all significantly enriched. Gene set enrichment
analyses (GSEA) further confirmed previously investigated upregulations in pathways
related to TNF- cytokine production, IL-6 production, and nitric oxide production (Fig
2.11C). Additionally, Reactome pathways CLEC7A dectin-1 signaling and C-type lectin
receptor pathways were significantly enriched, further corroborating the Dectin-1
involvement in this process (Fig 2.11D).
Considering that the myeloid population was observed to be responsible for the
expansion of the CD45+ population and that myeloid cells are a diverse population, CyTOF
analysis was performed on pancreata from mice treated with PBS or WGP 7 days prior.
Cell populations within the pancreas were identified and compared between treatment
groups; t-SNE plots indicate that following WGP treatment, numerous new populations of
myeloid cells are present in the pancreas due to WGP treatment (populations 11, 2, 6, 8, 9,
12, 13, 14, 15, and 17) which though heterogenous were characteristically defined by the
surface expression of Ly6C, F4/80, MHCII, CCR2, CD80, CD86 and PD-L1, indicative of
activated inflammatory macrophages and monocytes. These populations are highlighted
within the black circle (Fig 2.12, Fig 2.13). viSNE plots gated on the CD11b+ population
showed a distinct expansion of monocytes and macrophages, with additional increases of
the Dendritic Cell (DCs), neutrophil, and NK populations after WGP treatment (Fig
2.14A). Additionally, these analyses highlight that following WGP training and LPS
restimulation, TNF was primarily produced by macrophages and monocytes, IL-6 and
iNOS were primarily produced by macrophages, Granzyme-B was produced by NK-cells
and macrophages, and IFN was principally produced by neutrophils (Fig 2.14B). This
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reveals that while many cell populations are changed due to WGP treatment, the primary
cells trained by WGP, as assessed by increased TNF expression, are macrophages and
monocytes and that there is not a singular cell type responsible for the phenotype of the
trained immunity that was observed.

Myeloid cells in the pancreas are trained independently of adaptive immune
responses
To assess whether this phenomenon of myeloid cell influx and activation was
dependent upon other immune populations or driven entirely by the myeloid cells
themselves, we depleted specific immune populations and observed the trained phenotype.
Anti-CD4 and anti-CD8 mAbs were used alone and in combination to deplete T-cells, the
efficiency of depletion was assessed (Fig 2.15A), and the trained phenotype of myeloid
cells was observed (Fig 2.15B+C). NK cells were depleted using mAb PK136, the
depletion efficiency was evaluated (Fig 2.16A) and the trained phenotype was observed
(Fig 2.16B). In these depletion conditions, myeloid cells were still observed to be trained
by WGP. The trained phenotype was also assessed in NSG mice which lack B-cells, Tcells, and NK cells (Fig 2.17). These mice still showed a clear phenotype of trained
immunity. We also depleted neutrophils using Ly6G mAb. Despite depletion of
granulocytes, we still observed WGP-induced training in the CD11b+ myeloid
compartment (Fig 2.18). Taken together, our data support that the infiltrating myeloid cells
in the pancreas are trained by -glucan without the assistance or influence of adaptive
immune populations, NK cells, or granulocytes.
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A single-cell RNA sequencing reveals specific populations of pro-inflammatory
macrophage/monocytes that traffic to the pancreas upon -glucan treatment
To gain a more in-depth understanding of the cell populations present in the pancreas
after WGP treatment, a single-cell RNA sequencing (scRNA-Seq) was performed on sorted
CD45+ cells from PBS-treated mice and mice treated with WGP three (3-day WGP) and
seven days prior (7-day WGP). Two dimensional UMAP representation of 11,132 cells
aggregated from three samples (PBS=4213, 3-day WGP=3757, 7-day WGP=3244) with
clusters resulting from k-nearest neighbors and Louvain algorithms partitioned into 19
distinct clusters (Fig 2.19A+B). The relative frequency of each cluster within each
experimental group was assessed. Here, significant increases in the frequency of clusters
3,4, and 10 were observed by day 7 after WGP treatment, along with a near disappearance
of cluster 5 (Fig 2.19C). The relative frequencies of several other populations were also
shown to decrease over time. However, this apparent trend is likely due to the relative
increase in frequency of other populations. Overall, clusters 3,4,10 and 5 appear most
significantly altered due to WGP treatment (2.19C)
The populations noted previously to be most significantly altered over time due to WGP
treatment were part of the myeloid compartment, as identified by CSF1R expression (Fig
2.20A+B). As these data along with previous findings suggests that myeloid populations
drive the immune changes associated with WGP treatment, the dynamic CSF1R+ clusters
3,4,10 and 5 were investigated in more detail as shown by UMAP and violin plots (Fig
2.21A+B) and dot plots representing the top 12 marker genes by average Z-score for each
cluster (2.22A). Cluster 5, which was present in PBS mice but virtually disappeared after
WGP treatment was ITGAMIntADGRE1HiLyz2HiH2-Ab1HiLy6C2- and did not express
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TNFAIP2, indicating that these cells are resident macrophages [177, 178]. This cluster also
notably expressed MAF and APO which are both related to M2 macrophage polarization
[179-181]. Cluster 19 was largely unchanged over time so was not described in more detail,
but exhibited an expression profile similar to cluster 5, and thus also represents a subset of
tissue resident macrophages. Cluster 10 was characterized as ITGAMHiADGRE1HiLyz2Hi
H2-Ab1Int Ly6C2- with notable expression signatures of ARG1 and FABP. Clusters 3 and 4
share general phenotypic characterization as ITGAMInt ADGRE1Int Lyz2Hi H2-Ab1Int
Ly6C2Hi

CCR2Hi,

which

suggests

that

both

are

subsets

of

infiltrating

monocytes/macrophages. Cluster 4 had notable expression of Chil3 and Plac8, which
together have been identified by another group to identify Ly6Chi infiltrating macrophages
in the kidney [182]. Finally, cluster 3, which was absent in naïve mice and showed the
greatest increase in relative frequency among all clusters following WGP treatment
expressed substantial signatures of TNFAIP2, IL1B, SOD2, and PRDX5, indicating a
strongly pro-inflammatory phenotype. Cluster 3 was thus identified as inflammatory
infiltrating monocytes/macrophages. Interestingly, within the myeloid subset, the
populations shown to increase due to WGP treatment are the only populations to express
TNFAIP2, indicating that our previous use of TNF as a surrogate marker of trained
immunity was accurate.
To further characterize the activation status of each of the four dynamic myeloid
clusters, dot plots were constructed to show the relative expression of genes associated with
a pro-inflammatory status and an anti-inflammatory status (2.22B). Clusters 3 and 4, the
infiltrating monocytes/macrophages, were shown to be pro-inflammatory, the resident
macrophages were anti-inflammatory, and the macrophages in cluster 10 showed an
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intermediate phenotype. In agreement with previous CyTOF and flow cytometry data, this
scRNA-Seq data further characterize the newly identified pro-inflammatory monocytes
and macrophages in the pancreas due to WGP training.
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CHAPTER II FIGURES

Figure 2.1: IP WGP traffics to the bone marrow and causes an expansion of myeloid
progenitor cells
The bone marrow of mice injected with IP WGP or PBS was analyzed for (A) Lin-Sca-1+cKit+ (LSKs) and (B) CD48+CD150- MPPs 7 days after injection. (C) DTAF WGP was
injected IP and 3 days later the bone marrow was assessed for the presence of WGP. Data
are represented as mean ± SEM. ****p <.0001
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Figure 2.2: IP WGP causes an influx of CD11b+ myeloid cells into the pancreas
(A) WT mice were treated with I.P. DTAF-WGP and 3 days later the percent of
CD11b+DTAF+ cells in the pancreas were identified with flow cytometry. Cells were
previously gated on CD45+. (B) 7 days after I.P. PBS or WGP injection (7-day WGP), the
percent of CD45+ cells in the pancreas were identified. The percent of CD11b+, CD3+,
CD19+ and NK1.1+ cells within the CD45+ population were also measured. (C) The
absolute number of CD45+ immune cells, NK1.1+ NK cells, CD19+ B-cells, CD3+ T-cells,
CD11b+ myeloid cells in PBS and 7-day WGP trained mice. (D) 3 μm polystyrene beads
or PBS were injected IP and 7 days later the percent of CD45+ cells in the pancreas were
assessed. (E) Pie charts representing the relative change in frequency of each major
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CD3
CD19
CD11b
NK1.1

immune cell population between the PBS vs 7-day WGP treatment setting. Data are
represented as mean ± SEM. ns= not-significant; ****p <.0001
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Figure 2.3: A transient influx of diverse myeloid cell subtypes occurs after WGP
treatment
(A) WT mice were injected with WGP and the percent of CD45+ and CD45+CD11b+ cells
were measured 7, 10, 18, and 30 days later. These were compared to PBS treated mice. (B)
Gated on the pancreatic CD45+CD11b+ population, the percent of F4/80+ (macrophages),
Ly6C+ (monocytes) and Ly6G+ (neutrophils) were measured using flow cytometry. (C)
The absolute number of CD11b+F4/80+ macrophages, CD11b+Ly6C+ monocytes, and
CD11b+Ly6G+ neutrophils in PBS and 7-day WGP trained mice. Data are represented as
mean ± SEM. ns= not-significant; *p <.05, **p <.01, ***p <.001, ****p <.0001
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Figure 2.4: The trafficking of immune cells into the pancreas is dose dependent
The percent and absolute number of CD45+, CD45+CD11b+ and CD45+F4/80+ cells in PBS
mice and mice treated with .5, 1 and 2 mg of WGP.

Figure 2.5: The influx of immune cells is not C57BL/6 specific
Balb/c mice were given IP WGP and 7 days later the pancreata was harvested and the
percent of CD45+ cells were investigated. Data are represented as mean ± SEM., ****p
<.0001
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Figure 2.6: The WGP-driven influx of immune cells does not harm the pancreas
(A) A representative section from H+E imaging of the pancreas from PBS and 7-day WGP
trained mice. (B) The levels of amylase in the serum of PBS and 7-day WGP trained mice.
Data are represented as mean ± SEM. ns= not-significant;
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Figure 2.7: H+E imaging of PBS and WGP treated pancreases
(A) Mice were treated with PBS or WGP and 7 days later the pancreases were harvested
and analyzed to determine the location of the immuneological influx. (A) PBS v WGP
treated pancreases highlighting the fatty viscera that appears to be the target of immune
infiltration (B) Magnified imaging of immune infiltrates in WGP treated mice.
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Figure 2.8: Myeloid cells in the pancreas display features of trained immunity
Mice were trained with PBS or WGP. 7 days later mouse pancreas were harvested and
single-cell suspensions were restimulated with LPS. TNF production in CD11b+,
CD11b+F4/80+, and CD11b+Ly6C+ cells were measured using intracellular staining by
flow cytometry. Data are represented as mean ± SEM. ns= not-significant; *p <.05, **p
<.01, ***p <.001, ****p <.0001
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Figure 2.9: Enriched CD11b+ pancreatic cells show a phenotype of trained immunity
(A) 7 days after PBS or WGP training, the CD45+CD11b+ population was enriched using
FACS sorting. Cells were plated and restimulated with PBS or LPS for 24 hours and the
TNF and IL-6 in the supernatant were measured using an ELISA. (B) Pancreatic CD11b+
cells from PBS and WGP-trained mice were sorted using FACS and RT-qPCR was done
to quantify TNF, IL-6, iNOS and IL-10 mRNA expression levels. Data are represented
as mean ± SEM. ns= not significant; *p <.05, **p <.01, ***p <.001, ****p <.0001
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Figure 2.10: the induction of trained immunity in germ-free mice
Germ-free animals bred and maintained in the university of Louisville germ-free animal
facility were injected with WGP and 7 days later the pancreatic myeloid cells were
restimulated with LPS and the production of TNF was assessed. Data are represented as
mean ± SEM. **p <.01
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Figure 2.11: RNA-Seq analysis of PBS versus WGP treated pancreatic CD11b+ cells
Mice were trained with PBS or WGP and 7 days later the CD45+CD1b+ populations were sorted
and RNA-Seq analysis was performed (PBS n=3, WGP n=3). (A) The distribution of p values
(-log10(p value)) and fold changes (log2 FC) of differentially expressed genes in WGP vs PBS
trained cells are shown in a volcano plot. (B-D) Enrichment plots generated by Gene Set
Enrichment Analysis (GSEA) for genes related to (B) monocyte chemotaxis, mononuclear cell
migration, macrophage migration, leukocyte migration, leukocyte chemotaxis, and leukocyte
migration, (C) TNF and IL-6 production, and (D) Dectin-1 signaling in CD11b+ cells from
7-day WGP-trained as compared to PBS mice.
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Figure 2.12: Characterization of the pancreatic CD11b+ population using CyTOF
t-SNE plots of the CD11b+ population in mice trained with PBS or WGP 7 days prior and
analyzed with CyTOF (PBS n=3, WGP n=3). The black circle highlights new cell
populations in the pancreas following treatment with WGP
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Figure 2.13: Heatmap of the median scaled expression of the CyTOF markers in each
cluster determined from CyTOF workflow.
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Figure 2.14: Functional characterization of pancreatic CD11b+cells sing CyTOF
(A) viSNE plots of CD11b+ pancreatic cells in PBS and 7-day WGP trained mice, made
from CyTOF data, highlighting the specific expression of Ly6C, F4/80, CD11c, Ly6G and
NK1.1 in order to indicate the relative location of the major immune-cell subsets and
changes between the PBS and WGP treatment group. (B) viSNE plots of CD11b+
pancreatic cells in PBS and 7-day WGP trained mice, made from CyTOF data, showing
the expression of TNF, IL-6, Granzyme-B, iNOs and IFN.
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Figure 2.15: Training of pancreatic myeloid cells is not dependent on T-cells
(A) Representation of the T-cell depletion efficiency in the spleen of anti-CD-4 and cntiCD-8 mAbs used in vivo. (B+C) Mice depleted of CD4+ T-cells, CD8+ T-cells or both
CD4+ and CD8+ T-cells and WT mice were given I.P. WGP and 7 days later the pancreatic
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production in the CD11b+ cells was measured by flow cytometry. Summarized data is
shown. Data are represented as mean ± SEM. ****p <.0001
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Figure 2.16: Training of pancreatic myeloid cells is not dependent on NK cells
(A+B) NK-cell depleted mice and WT mice were treated with PBS or WGP and 7 days
later the pancreatic cells from these mice were restimulated with LPS. TNF production
in the CD11b+ cells was measured by flow cytometry. Summarized data is shown. Data
are represented as mean ± SEM. ns= not-significant; *p <.05, **p <.01, ***p <.001,
****p <.0001
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Figure 2.17: Adaptive immune responses to not involved in the training of pancreatic
CD11b+ myeloid cells
NSG mice were injected with PBS or WGP and 7 days later pancreatic cells were
restimulated with LPS. TNF production in the CD11b+ cells was measured by flow
cytometry. Representative and summarized data are shown. Data are represented as mean
± SEM., **p <.01
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Figure 2.18: Training of pancreatic myeloid cells is not dependent on granulocytes
(A) The depletion efficiency of an anti-ly6G mAb and its isotype control (anti-rat IgG2a)
was assessed in the mouse pancreas. (B) Mice treated with the anti-Ly6G mAb and isotype
control were given either PBS or WGP and 7 days later pancreatic cells were restimulated
with LPS. TNF production in the CD11b+ cells was measured by flow cytometry.
Summarized data is shown. Data are represented as mean ± SEM. ***p <.001, ****p
<.0001
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Figure 2.19: Single-cell RNA-Seq showing the immune cell phenotype 3 and 7 days
following IP WGP
CD45+ cells from the pancreas of mice treated with PBS or WGP 7 days and 3 days prior
were sorted and scRNA-Seq was performed. (A)Two dimensional UMAP representation
of 11,132 cells aggregated from the three experimental samples with 20 unique clusters
resulting from k-nearest neighbors and Louvain algorithms. (B) Heatmap of expression of
aggregated marker genes for all clusters. (C) Bar graphs showing the relative frequency of
cells in each cluster across samples.
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Figure 2.20: scRNA-Seq identifies CSF1R+ myeloid populations that are increased
following WGP treatment
CD45+ cells from the pancreas of mice treated with PBS or WGP 7 days and 3 days prior
were sorted and scRNA-Seq was performed. (A) UMAP dimension reduction of PBS
(blue), 3-day WGP (green) and 7-day WGP (red) samples shown individually. The portion
of the UMAP representing myeloid cells is highlighted. (B) Single-cell gene expression of
CSF1R.
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Figure 2.21: Classification of differentially regulated myeloid populations in the
pancreas using scRNa-Seq
CD45+ cells from the pancreas of mice treated with PBS or WGP 7 days and 3 days prior
were sorted and scRNA-Seq was performed. (A) Single-cell expression distributions across
clusters identified as myeloid cells for select genes related to myeloid phenotyping. (B)
CCR2 expression throughout the differentially regulated myeloid population.
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Figure 2.22: Characterization of differentially regulated myeloid populations in the
pancreas using scRNA-Seq
CD45+ cells from the pancreas of mice treated with PBS or WGP 7 days and 3 days prior
were sorted and scRNA-Seq was performed. (A) Dot plot of the top 12 enriched genes in
cluster 3,4,5 and 10 showing the average expression level and percentage of cells
expressing select genes. (B) Dot plots showing the enrichment of selected genes associated
with pro-inflammatory (green) and anti-inflammatory (red) immune responses across
clusters 3,4,5 and 10. The average expression level is displayed as z-scores computed
across the four clusters for individual genes.
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CHAPTER II DISCUSSION

While it was expected that WGP trafficking to the pancreas would result in
immunological changes to the resident populations there, it was surprising to observe such
a profound influx of innate immune cells to the pancreas. DTAF-WGP studies demonstrate
that while macrophages that have phagocyted WGP traffic to the pancreas, there also exists
a population of CD11b+ myeloid cells that traffic to the pancreas that have not
phagocytosed WGP. It is likely that the trafficking of peritoneal macrophages that have
phagocytosed WGP to the pancreas incites the production of cytokines and chemokines
that then recruit additional myeloid cells there. Despite the presence of these myeloid cells,
importantly, both short-term and long-term observation of mice show that this WGP-driven
influx of immune cells into the pancreas does not cause morbidity or mortality in mice.
Serum amylase levels were not increased, which would be indicative of pancreatic
destruction or pathological pancreatitis.
Preliminary H+E imaging of WGP-treated pancreases showed an accumulation of
immune cells in a fatty layer attached to the pancreas. We hypothesized this to be part of
the greater omentum, a fold of visceral peritoneum that attaches to the pancreas in mice.
The greater omentum has been known to have immunogenic properties and has also been
shown to be a destination of activated peritoneal macrophages[183, 184]. To explore this
further we performed omentectomies on mice where we detached the omentum from the
pancreas and removed the distal fold of the tissue. After one week had passed, we injected
WGP in an effort to investigate whether the omentum was a critical pathway in WGP-
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trafficking to the pancreas. Despite the lack of a greater omentum, DTAF-WGP still
trafficked to the pancreas and CD11b+ myeloid cells still accumulated in the pancreas,
though the inflammation caused as a result of the procedure made a full analyses of the
pancreas challenging. Kubes et al had reported that in the setting of liver injury, large
GATA6+ peritoneal macrophages take an avascular route of migration to the liver where
they traffic to and through the visceral endothelium that covers the liver within one hour
following the induction of sterile injury[164, 185]. These findings highlight a non-vascular
recruitment of immune cells to visceral organs that could be related to the influx of immune
cells observed in this model. While chapter 3 of this dissertation will address some of the
signaling mechanisms involved in recruiting innate immune cells to the pancreas, it still
remains unknown why WGP traffics to the pancreas or why macrophages that have
phagocytosed WGP also traffic there.
Following WGP treatment, myeloid cells within the pancreas were shown to exhibit a
trained phenotype upon LPS restimulation that was not dependent on any adaptive immune
populations. More in depth investigations using CyTOF, RNA-Seq and scRNA-Seq data
together confirmed that WGP led to the upregulation in a number of genes associated with
trained immunity and enhanced effector function.

4 myeloid populations exhibited

noteworthy dynamic behavior following WGP treatment, several of which have not been
previously

identified

in

the

mouse

pancreas.

First,

cluster

5

which

was

ITGAMIntADGRE1HiLyz2HiH2-Ab1HiLy6C2- was present in PBS mice and virtually
disappeared following WGP treatment. Their presence in the pancreas of WT mice along
with high F4/80 expression, and low Ly6C expression designate cluster 5 as resident
macrophages. In line with the literature, these cells strongly exhibited markers of M2
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polarization [186]. Resident macrophages of the pancreas are known to exhibit M2
polarization as these cells are involved in would healing and tissue repair [187]. Cluster
10, defined by the expression of ITGAMHiADGRE1HiLyz2Hi H2-Ab1Int Ly6C2- is absent in
PBS treated mice and appears at day 3 after WGP treatment. This population has a similar
expression profile to cluster 5 (ITGAMIntADGRE1HiLyz2HiH2-Ab1HiLy6C2-), the
alternatively activated M2 resident macrophage population, though cluster 10 appears to
skew more towards an M1 classically activated macrophage phenotype. The reciprocal
increase in cluster 10 and decrease in cluster 5 at days 3 and 7 post-WGP treatment along
with a lack of CCR2 expression suggest that cells in cluster 10 could be resident
macrophages that have been trained by the -glucan, and subsequently adopts an activated
phenotype, thus forming a new cluster. While further studies are warranted to investigate
whether resident macrophages in the pancreas are impacted by WGP, given the relative
disappearance of the resident population following WGP treatment it is likely that this is
the case.
Cluster 3 and 4 were both classified as types of inflammatory macrophages/monocytes
based on the expression of ITGAMInt ADGRE1Int Lyz2Hi H2-Ab1Int Ly6C2Hi along with high
expression of TNFAIP2 and CCR2. Cluster 3, a novel pancreatic population which exhibits
the most evident features of trained immunity is absent in naïve mice and becomes the
cluster with the highest relative frequency by day 7 after WGP administration. Recent
studies into the mechanism of trained immunity show that after -glucan administration,
monocytes from trained HSCs in the bone marrow can migrate to peripheral organs where
they become monocyte-derived macrophages that not only are longer lived than typical
monocytes, but that also possess features of trained immunity [188, 189]. Given the trained
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phenotype, the high expression of CCR2, and that the majority of the influx of this
population happens more than 3 days following WGP administration, we speculate that
cluster 3 and 4 may represent such BM-derived cells that are directed to the pancreas
shortly after WGP arrives there. This development of peripheral trained immunity has been
described in several tissues but has not been previously identified to exist in the pancreas
[190, 191].
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CHAPTER III
WGP-INDUCED TRAFFICKING OF IMMUNE CELLS TO THE PANCREAS IS
CCR2 DEPENDENT

CHAPTER III INTRODUCTION
After discovering that the two most prominent cell populations to traffic to the pancreas
due to WGP treatment were macrophage/monocyte populations that highly expressed
CCR2, we wanted to know whether CCR2 signaling may be responsible for this influx of
cells into the pancreas. CCR2 is known to be highly expressed on blood monocytes, and
CCR2-/- mice are known to have increased numbers of monocytes in the BM, suggesting
that CCR2 expression is critical to monocyte egress from the BM [192]. Monocyte
chemoattractant protein-1 (MCP-1), also known as CCL2, is the primary ligand for CCR2,
and is expressed by a variety of cell types including endothelial cells, smooth muscle,
fibroblasts [193, 194], tumor cells [195] and myeloid cells. CCL2 is best known as a
chemoattractant, where its expression induces monocyte adhesion to the vascular
endothelium, extravasation through blood vessels and chemotaxis to tissues with high
CCL2 concentrations [196]. Overall, CCL2 expression is critical in both recruiting
circulating monocytes from the periphery to a site of inflammation, and in mobilizing
CCR2+ monocytes from the bone marrow [192]. Given the observed recruitment of
monocytes and monocyte-derived macrophages to the pancreas following WGP injection,
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we hypothesized that CCR2/CCL2 signaling may be important in the recruitment of
these cells.

CHAPTER III RESULTS

To investigate the mechanism of myeloid cell recruitment to the pancreas, RNA-Seq
data was used to characterize chemokines and cytokines whose expression was
significantly upregulated upon WGP treatment (Fig 3.1A), and scRNA-seq data was used
to investigate which cells might be responsible for this upregulation (Fig 3.1B).While
several chemokines and cytokines were upregulated, our observation of macrophage and
monocyte influx into the pancreas piqued a specific interest in CCR2 due to its involvement
in monocyte and macrophage recruitment and in monocyte egress from the bone marrow
[197-199]. CyTOF data also showed a prominent increase in CCR2 positive cells after
WGP treatment (Fig 3.2A) and scRNA-Seq showed a distinct expression of CCR2 in
clusters 3 and 4, which were the two populations that showed the most distinct phenotypes
of trained immunity (Fig 3.1B). Additionally, 24 hours post-WGP treatment, whole
pancreatic lysates showed a 30-fold increase in CCL2, which is the ligand for CCR2 and
is involved in mediating monocyte chemotaxis (Fig3.2B)
While RNA-Seq data had shown a clear signature of immune cell recruitment and
trafficking, these data had also indicated that WGP upregulated proliferation of leukocytes
and mononuclear cells (Fig 3.3A). To investigate whether the CCR2+ myeloid cells were
proliferating once they reached the pancreas, WT mice were treated with WGP or PBS and
7 days later pancreatic cells were assessed for Ki67 expression. Cells were first gated on
the CD45+Ki67+ population, and these were then gated on CD11b vs CCR2 to determine
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what percent of the proliferating cells were CCR2+ myeloid cells. Following WGP
treatment there was an increase in overall proliferating cells (Fig 3.3B) and a large percent
of these proliferating cells were CD11b+CCR2+ (Fig 3.3C). We then investigated the
contribution of CCR2+ cells to the trained phenotype. 7 days after in vivo treatment with
PBS or WGP, CCR2+ and CCR2– populations were measured for trained response (Fig
3.4). This data indicated that the majority of cells trained following WGP treatment were
CCR2+. To further examine the role of CCR2 in -glucan trained monocytes/macrophages,
CCR2-/- mice were trained with WGP -glucan. CCR2-/- mice did not undergo an influx of
CD45+ (Fig 3.5A) or CD45+CD11b+ myeloid cells (Fig 3.5B) into the pancreas, and did
not show a trained response as revealed by TNF- production (Fig 3.5C). This data
indicates that CCR2 plays a critical role in the migration of innate immune cells to the
pancreas and in the induction of peripheral trained immunity in the pancreas.
As previously noted, CCR2 is important for early recruitment of monocytes, but less
so for late recruitment [200]. Thus far, we had also observed that at 7 days following WGP
training, CCR2 was critical to the recruitment of trained myeloid cells to the pancreas. We
next examined whether this influx occurred at an early time point upon WGP training and
whether the CCR2+ myeloid cells were recruited to the pancreas. To this end, mice were
treated with PBS or WGP and pancreatic tissues were analyzed 24 and 48 hours later.
Surprisingly, as early as 24 hours after WGP training, increases in CD45+ (Fig 3.6A),
CD11b+ (Fig 3.6B), F4/80+ (Fig 3.6C), Ly6C+ (Fig 3.6D) and CD11b+CCR2+ (Fig 3.6E)
cells were observed. Additionally, it was shown that these myeloid cells were also trained
as early as 24 hours following WGP treatment. This observation highlights a divergence
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between these results and previously observed phenotypes of trained immunity which
usually are not initiated until at least 3 days following training (Fig 3.6F).

CHAPTER III FIGURES
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Figure 3.1: Chemokines and cytokines upregulated by WGP treatment
(A) Heatmap of chemokines and cytokines that were upregulated in 7-day WGP treated
CD11b+ cells based on RNA-Seq data (B) scRNA-Seq data showing a UMAP of the
myeloid cluster expression of chemokines and chemokine receptors.
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Figure 3.2: CCR2/CCL2 signaling is increased due to WGP treatment
(A) viSNE plot of the CD11b+ pancreatic population in PBS and 7-day WGP-trained mice,
highlighting the expression of CCR2. Images made with CyTOF data. (B) CCL2
expression in whole pancreatic lysates 24 hours following WGP treatment a measured by
RT-PCR.
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Figure 3.3: Proliferation of CCR2+ cells in the pancreas
(A) GSEA generated enrichment plots of genes related to leukocyte proliferation in
CD11b+ pancreatic cells from 7-day WGP-trained as compared to PBS mice. (F)
Summarized data of the percent of CD45+ pancreatic cells that are Ki67+ in PBS and 7day WGP-trained mice. (B) Cells were first gated on the CD45+Ki67+ population. Plots
show the percent of the CD45+Ki67+ proliferating pancreatic cells that are CD11b+CCR2+
in PBS and 7-day WGP-trained mice. Data are represented as mean ± SEM. *p <.05, **p
<.01.
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Figure 3.4: CCR2+ cells in the pancreas are trained due to WGP
Pancreatic cells from PBS and 7-day WGP-trained mice were restimulated with LPS and
the percent of CCR2 positive and negative cells producing TNF was measured in each
condition. Cells were first gated on the CD45+CD11b+ subset. Data are represented as mean
± SEM. ns= not significant;, **p <.01, ***p <.001,
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Figure 3.5: cellular influx and training of pancreatic innate myeloid cells do not occur
in CCR2-/- mice
(A-C) WT and CCR2-/- mice were treated with PBS or WGP and the percent of (A) CD45+
cells in the pancreas (B) and the percent of CD45+ cells that were CD11b+ was assessed.
(C) The percent of CD45+CD11b+ cells producing TNF. Data are represented as mean ±
SEM. ns= not significant; ***p <.001,
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Figure 3.6: Pancreatic myeloid cells
are trained by 24 and 48 hours postWGP
Mice were treated with WGP 24 hours
or 48 hours before euthanization and the
percent of (A) CD45+, (B) percent of
CD45+ cells that were CD11b+, (C)
percent of CD45+CD11b+ cells that were
F4/80+

and
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CD45+CD11b+ cells that were Ly6C+
cells were measured and compared to
that of a PBS treated mouse. (E)
Pancreatic cells from PBS and 24 and
48 hour WGP treated mice were gated
on the CD45+ population and the
percent of these cells that were
CD11b+CCR2+

was

assessed.

(F)

Pancreatic cells from PBS and 24 and
48 hour WGP treated mice were
restimulated with LPS and the production of TNF was measured. All analyses were done
by flow cytometry and representative and summarized data are shown. Data are represented
as mean ± SEM. ns= non-significant; *p <.05, **p <.01, ***p <.001, ****p <.0001
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CHAPTER III DISCUSSION

24 hours following the administration of WGP, CCL2 levels in whole pancreatic lysates
were found to be increased by 30 fold. Accordingly, we show that the recruitment of
immune cells and the establishment of this peripheral trained immunity in the pancreas is
dependent on CCR2 signaling. We also show that CCR2+ cells account for the majority of
cells that are trained following WGP treatment. Together this suggests that WGP
trafficking to the pancreas upregulates CCL2 signaling which then is sufficient to recruit
CCR2+ trained cells from the bone marrow to the pancreas. Though peripheral trained
immunity has been documented, the specific signaling mechanism responsible for the
recruitment of trained innate cells from the bone marrow to a specific organ to establish
peripheral trained immunity has not been well defined. We speculate that cluster 3 and 4,
from the scRNA-seq data, may likely represent such BM-derived cells that are directed to
the pancreas due to the CCL2 signaling that occurs shortly after WGP arrives there. These
subsets of cells are only present more than 3 days following WGP treatment and show high
levels of CCR2, an M1 polarization phenotype and gene upregulations consistent with the
induction of trained immunity.
As after WGP treatment we had observed a disappearance of the resident macrophage
population, likely due to a phenotypic shift, we did wonder whether resident macrophages
may be involved in the initiation of CCL2 production that recruits CCR2+ cells to the
pancreas. To address this we tried to deplete resident pancreatic macrophage populations,
however this proved to be challenging. The use of both liposomal clodronate and antiF4/80 mAb depleted macrophages systemically, such as in the spleen, but was not effective
at depleting the pancreatic resident population. Further experiments are needed to
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determine if the peritoneal macrophages that phagocytose WGP, resident macrophages or
other cell types in the pancreas are responsible for initiating CCL2 signaling. CCL2 is also
highly produced by stromal cells, so it may be the case that resident macrophage
populations do not directly secrete CCL2, but rather impact other cell types within the
pancreas to produce CCL2.
We also showed that CCR2+ cells account for a large percent of the proliferating Ki67+
cells in the pancreas following WGP training. Taken together these results suggest that the
increase in trained myeloid cells may be due to several mechanisms including the influx of
peritoneal macrophages, trafficking of CCR2+ cells to the pancreas from the periphery, and
through in situ expansion of trained resident macrophages. Notably, the currently reported
study is the first time that CCR2 has been identified as a requisite to the establishment of
organ-specific peripheral trained immunity.
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CHAPTER IV
THE ANTI-TUMOR ROLE OF -GLUCAN-INDUCED TRIANED IMMUNITY IN
PANCREATIC CANCER

CHAPTER IV INTRODUCTION
Our investigations up to this point have shown that WGP treatment incites an influx
of myeloid cells into the pancreas that show a phenotype of trained immunity and M1
polarization. Not only this, but WGP trafficking to the pancreas was also shown to
reprogram the M2 resident macrophages of the pancreas into a more inflammatory
phenotype. Moreover, these studies revealed in both in vitro and in vivo settings that
pancreatic CD11b+ cells that had been exposed to WGP produced increased antiinflammatory cytokines, such as TNF- and IL-6, upon re-exposure to a secondary
stimulus, LPS. It is known that there are a plethora of stimuli that can serve as the second
signal in -glucan-induced trained immunity. However, the majority of studies have used
bacteria or viruses as a secondary stimulus, and thus have been mainly been targeted at
understanding whether the induction of trained immunity may be useful against pathogenic
infections. Further, while the two studies regarding trained immunity and cancer discussed
in the introduction do investigate whether the induction of trained immunity in mice can
lead to anti-tumor effects, they do not directly investigate if the trained response can be
directly elicited by exposure of trained cells to a tumor cell or the soluble factors that tumor
cells secrete. We hypothesized that tumor cells and their soluble factors may function as
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an effective second signal to cells previously trained by -glucan (Fig 4.1).
Additionally, given the influx of trained immune cells that we had observed, in this chapter
we will explore the anti-tumor mechanisms of trained immunity specifically in a model of
orthotopic pancreatic cancer.

CHAPTER IV RESULTS

WGP-trained pancreatic infiltrating myeloid cells elicit potent trained responses to
factors secreted from pancreatic cancers and exhibit enhanced phagocytosis and
ROS-mediated cytotoxicity
As we have shown that using WGP as an initial stimulus results in innate immune cells
that are trained to respond more robustly to a secondary exposure of LPS, and that these
cells accumulate in the pancreas following treatment, we wanted to know whether
secondary stimuli related to pancreatic tumors may also elicit this trained response. To this
end, we first investigated whether pancreatic cancer cells themselves are capable of
eliciting the WGP-induced trained response. To probe this question, peritoneal
macrophages were cultured with PBS or WGP in vitro for 24 hours and then washed,
followed by a 7-day resting period. On day 7, cells were restimulated with LPS, the
supernatant from cells cultured from a naïve mouse pancreas, and the supernatant from
cultured KPC cells, which are a cell line of a pancreatic tumor on a C57BL/6 background
derived from the LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx1-Cre (KPC) or Pan02 pancreatic
cancer cells for 24 hours. TNF- production in the supernatant was measured by ELISA.
Compared to the supernatant from cultured normal pancreatic cells which did not activate
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previously trained macrophages, the supernatant from cultured KPC and Pan02 pancreatic
cancer cells stimulated more TNF- production in -glucan trained macrophages (Fig
4.2A). To control for the possibility that the process of phagocytosis itself may cause cells
to become activated, peritoneal macrophages were cultured with 3m polystyrene
microparticle beads, the cells were allowed to rest for 7 days, and cells then were
restimulated with PBS or LPS (Fig 4.2B). Results showed that enhanced production of
TNF was specific to WGP training.
This was then tested in an ex vivo setting in which mice were treated with PBS or WGP
and 7 days later pancreatic myeloid cells were harvested and restimulated with the
supernatants from cultured KPC (Fig 4.3A) or Pan02 cells (Fig 4.3B). It showed that WGP
in vivo trained CD11b+ myeloid cells in the pancreas produced significantly more TNF-
in response to tumor-conditioned media.
We had shown that tumor cell supernatants function as secondary stimulus to trained
cells, however there are a multitude of factors within the tumor conditioned media that may
specifically function as the second stimulus in trained immunity. It is known that pancreatic
tumor cells express high levels of damage-associated molecular patterns (DAMPs) and
pro-inflammatory factors, and we hypothesized that some of these specific factors may
evoke the trained response. KPC cells are known to secrete high levels of both macrophage
migration inhibitory factor (MIF) and high mobility box protein-1 (HMGB1). MIF is a
cytokine that is known to be secreted in high concentrations by pancreatic tumors that can
act directly on myeloid cells [201, 202]. Indeed, MIF was present in the supernatant of
KPC and Pan02 cells as assessed by ELISA (Fig 4.4A). We thus hypothesized that MIF
might be a potential tumor-secreted factor that has the capacity to act as a second signal in
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the setting of WGP-induced trained immunity. To investigate this, pancreatic myeloid cells
from in vivo WGP-trained mice were restimulated with a similar concentration of
recombinant MIF (rMIF) as present in tumor conditioned media. As shown in Fig 4.4B,
pancreatic myeloid cells previously trained with WGP showed enhanced TNF-
production upon rMIF restimulation. Re-stimulating WGP-trained cells with HMGB1 also
was shown to elicit the trained response (Fig 4.5). Collectively, these data suggest the novel
concept that pancreatic tumor cells, through soluble factors that they release, can serve as
the second signal to activate myeloid cells in the pancreas that have been trained by WGP.
We next examined whether these WGP-trained innate immune cells have enhanced
intrinsic anti-tumor properties. RNA-Sequencing data indicated that phagocytosis-related
mechanisms were upregulated in the WGP setting, which we hypothesized could be one
mechanism of anti-tumor functionality (Fig 4.6). CD45+ pan immune cells and CD11b+
myeloid cells from WGP-trained mouse pancreas were harvested and assayed for
phagocytotic potential using the Invitrogen pHrodoTM Green S. aureus BioParticlesTM
Phagocytosis Kit. WGP treatment led to a significant increase in the phagocytic potential
of overall CD45+ immune cells (Fig 4.7A) and in CD11b+ myeloid cells (Fig 4.7B). In
addition, in vivo trained myeloid cells showed an increase in the phagocytosis of KPC
tumor cells (Fig 4.8). We then assessed whether myeloid cells trained by WGP show an
increased cytotoxicity to KPC cells. RNA-Seq data indicated that DEGs related to reactive
oxygen species (ROS) biosynthetic processes and positive regulation of ROS metabolic
processes were significantly enriched in WGP-treated myeloid cells (Fig 4.9A). As a result,
we hypothesized that the upregulation of ROS production by WGP would result in
increased pancreatic myeloid cell cytotoxicity to KPC tumor cells. To explore this
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hypothesis, CD11b+ cells from the pancreas were isolated from -glucan trained or
untrained mice. Acquiring enough CD11b+ cells from an untrained mouse pancreas was
challenging, as only 1% of total cells are CD45+ in pancreas. As such, our assay was limited
to a maximum of 1:20 for the tumor cell:CD11b+ cell ratio. CD11b+ cells were plated with
luciferase expressing KPC cells (KPCLuc+) for 24 hours. The luciferase released into the
supernatant was quantified using the Luciferase Assay Reagent. WGP-trained myeloid
cells showed a 3-fold increased cytotoxicity towards KPC tumor cells, and the inhibition
of ROS production using the ROS inhibitor N-Acetyl Cysteine (NAC) completely
abrogated the WGP-elicited increase in cytotoxicity (Fig 4.9B). Ultimately, these data
identifies that pancreatic tumor cells are capable of reactivating WGP-trained infiltrating
myeloid cells in the pancreas, and that these cells show enhanced phagocytosis and ROSmediated cytotoxicity.

WGP-induced trained immunity reduces tumor growth and prolongs survival in
orthotopic models of pancreatic cancer
We next investigated whether -glucan-mediated trained innate immune responses in
the pancreas would result in the establishment of an anti-tumor microenvironment that may
be sufficient to overcome the characteristically immunosuppressive TME of PDAC.
Accordingly, mice were given 1 dose of either PBS or WGP on day -7 and on day 0, 1x105
KPC or KPCLuc+ cells were orthotopically implanted into the tail of the pancreas (Fig
4.10A). At day 21 mice were euthanized and the tumor weight was measured or (Fig
4.10B). In the setting of injection of KPCLuc+ cells, mice were injected with luciferase
substrate and tumors were imaged. The tumor burden was assessed through quantification
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of photon counts/second (Fig 4.10C). Both studies showed a remarkable reduction in tumor
burden as a result of WGP treatment, and survival was also significantly prolonged in mice
trained with WGP (Fig 4.10D). Immunophenotyping of the tumors showed a persistent
increase in CD45+ immune cells, CD11b+ myeloid cells and F4/80+ macrophages in the
WGP-trained setting (Fig 4.11A). CD11b+ myeloid cells (Fig 4.11B) and CD11b+F4/80+
macrophages (Fig 4.11C) within the tumor also showed a significant increase in TNF-
production due to WGP. Both an increased number of CD11b+ myeloid cells (Fig 4.11D,
left) and an increase in the percent of CD11b+ cells producing TNF- (Fig 4.11D, right)
significantly correlated with decreased tumor burden. Neither CD4+ nor CD8+ T-cells
showed increased IFN-, further supporting that the reduction in tumor burden was driven
by the WGP-trained myeloid cells (Fig 4.11E). Similar antitumor effects were also
observed in mice orthotopically implanted with Pan02 tumors (Fig 4.12A). To further
confirm that innate immune cells are responsible for the observed anti-tumor immune
responses, orthotopic KPC tumors were implanted into NSG mice. Similar to WT mice,
NSG mice also showed a significant reduction in tumor size due to WGP training,
confirming that the anti-tumor effects of WGP were driven by innate immune cells and
functioned independently of adaptive responses (Fig 4.12B). Kalafati et al had shown that
innate immune training of granulopoiesis promotes anti-tumor immunity [203]. While we
had not seen an important contribution of granulocytes to our phenotype of trained
immunity, we examined whether granulocytes are involved in WGP-dependent reduction
in pancreatic tumors. We administered anti-Ly6G mAb or isotype control mAb on day -2,
4, 10 and 16, injected mice with PBS or WGP on day 0 and implanted orthotopic KPC
tumors on day 7. The depletion efficiency of neutrophils in the pancreas (Fig 4.12A) along
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with the pancreatic tumor burden were assessed (Fig 4.13B). Our results showed a
significant reduction in tumor size in the WGP group in the absence of neutrophils.
Given that a complete inhibition of innate immune cell trafficking into the pancreas
and training of pancreatic myeloid cells following WGP treatment in CCR2-/- mice, we
reasoned that CCR2-/- mice would also not show the beneficial anti-tumor immune effects
of WGP training. In line with this hypothesis, CCR2-/- mice that received WGP did not
show a reduced tumor burden (Fig 4.14) as compared to WT mice. We also utilized an
admix model where sorted CD11b+ CCR2- and CCR2+ cells were mixed with KPC tumor
cells and implanted orthotopically into WT mice. Tumors implanted with CCR2+ cells
showed a decreased tumor burden (Fig 4.15) Together, these findings demonstrate that
CCR2 is requisite for the WGP-driven influx of trained innate immune cells into the
pancreas and that those are consequential for the anti-tumor effects. CyTOF was also
performed on these samples to see if there were phenotypic differences. A significant
increase in the relative frequency of CD8+ T-cells and a decrease in the relative percent of
CD11b+ myeloid cells were observed in the tumors that had been admixed with CCR2+
cells (Fig 4.16).
Though CCL2-CCR2 signaling had been identified to be critical in the recruitment of
trained monocyte-derived macrophages to the pancreas, we also wanted to know whether
the presence of trained HSCs in the bone marrow alone was sufficient to recruit CCR2+
cells to the pancreas to slow the growth of orthotopic pancreatic tumors. A BM chimera
model was used where B6/SJL (CD45.1) mice were treated with PBS or WGP and 7 days
later their BM was harvested and transplanted into lethally irradiated (950 cGy) WT
(CD45.2) mice. Six weeks following transplantation, recipient mice were implanted with
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orthotopic KPC tumors and tumor size was assessed 14 days later (Fig 4.17). Tumor size
between the two groups was the same. First, this indicates that the mechanism of peripheral
trained immunity in the pancreas is different than other models of trained immunity which
appear to be entirely driven by the induction of trained immunity in the bone marrow.
Second, this shows that the trafficking of WGP to the pancreas, which upregulates CCL2
signaling, is likely necessary to recruit trained monocytes from the bone marrow directly
to the pancreas.

Trained innate immunity synergizes with anti PD-L1 mAb therapy to prolong
survival and can also be used in the treatment setting
Although the significant reduction in tumor burden was shown due to WGP training, it
is the case that all mice developed fatal tumors. Through scRNA-Seq analysis, we observed
a distinct expression of CD274 (PD-L1) on myeloid clusters (Fig 4.18A). RNA-Seq data
also showed that CD274 was upregulated following WGP training (p = 3.37x10-4).
Analyses of orthotopic KPC tumors also indicated that while the tumor cells themselves
did express some PD-L1, macrophages and DCs in the TME expressed the highest levels
of PD-L1 (Fig 4.18B). This is important as it has been reported that host expression of PDL1 determines the efficacy of PD-L1 pathway blockade-mediated tumor regression. This
leads us to hypothesize that WGP training may act synergistically with anti-PD-L1 mAb
to further prolong mouse survival [204].
To assess whether anti-PD-L1 mAb therapy synergizes with WGP-induced trained
immunity in the pancreas, mice were given WGP on day -7, implanted with orthotopic
KCP tumors on day 0 and were then given 3 treatments of either anti PD-L1 mAb or rat
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IgG2b isotype control mAb. As has been shown in several clinical trials, anti-PD-L1
therapy alone failed to prolong survival even beyond that of the IgG2b isotype control mAb
treated mice (Fig 4.18C). WGP-trained mice did survive significantly longer than IgG2b
isotype and anti-PD-L1treated mice. However, combination of WGP and anti-PD-L1
together prolonged survival most effectively. This shows that there is a clinical benefit to
combining WGP with anti PD-L1 immuno-checkpoint blockade therapy.
Thus far, the use of WGP has been described in a setting in which WGP is administered
before tumor cells are implanted. Considering the reduction in tumor size of this model,
we also tested a more clinically relevant model in which mice were implanted with
orthotopic KPC tumors and WGP was used to incite trained immunity thereafter. Two
doses were given; the first after mice had recovered from surgery and a second one week
later (Fig 4.19). In the therapeutic setting, the WGP-driven influx of trained myeloid cells
to the pancreas was also shown to prolong survival. Together, these data suggest that the
initiation of trained immunity in the pancreas using WGP has relevant clinical applications
in treating pancreatic cancer that necessitate further translational research and
investigation. Finally, we wanted to investigate whether WGP combined with anti-PD-L1
may prolong survival in the therapeutic setting so mice were treated with WGP on day 4
and 11 following tumor implantation, and were then given three doses of anti-PD-L1.
Similar to previous results, mice treated with monotherapy of anti PD-L1 did not have a
survival benefit beyond untreated mice, WGP treated mice did show prolonged survival as
compared to PBS and anti-PD-L1 treated mice, and mice treated with WGP and PD-L1
showed the most prolonged survival (Fig 4.20).
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CHAPTER IV FIGURES

Figure 4.1: Schematic of the anti-tumor effects of WGP-induced trained immunity in
the setting of pancreatic cancer
Injection of WGP and trafficking of WGP to the pancreas causes the influx of trained innate
immune cells to the pancreas. These cells have gone epigenetic, metabolic, mitochondrial
and transcriptional reprograming and when they then come into contact with pancreatic
tumor cells, the trained cells are re-stimulated.

88

150

TNF-a (pg/ml)

B

In vitro training of
peritoneal macrophages

*

ns
250

*
TNF-a (pg/ml)

A

**

100

ns

50

ns
0

***
***

200
150
100
50
0

PB
S PB
+ S
LP
Be
S
ad Be
+ ad
LP
W W S
G G
P P
+
LP
S

S P p p S S C C 02 02
PB WG Su Su LP LP KP KP an an
nc nc BS GP S P S P P P
P a l P a P W P B WG P B G
l
W
a a
m m
or or
N N
S P
P B WG

Figure 4.2: Tumor conditioned media elicits a trained response in vitro
(A) Peritoneal macrophages were acquired from WT mice and were stimulated in vitro
with PBS or WGP for 24 hours. Cells were allowed a resting period of 7 days followed by
restimulation with PBS, LPS, the supernatant from cultured and untreated pancreatic cells,
or the supernatant from cultured KPC or Pan02 pancreatic cancer cells for 24 hours. The
amount of TNF released over the 24 hours was quantified using an ELISA. (B) Peritoneal
macrophages were acquired from WT mice and were stimulated in vitro with PBS, WGP,
or 3 μm polystyrene beads for 24 hours. Cells were allowed a resting period of 7 days
followed by a 24 hour restimulation with PBS or LPS. The amount of TNF released over
the 24 hours was quantified using an ELISA. Data are represented as mean ± SEM. ns=
non-significant; *p <.05, **p <.01, ***p <.001, ****p <.0001
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Figure 4.3: Tumor conditioned media elicits a trained response ex vivo
(A+B) WT mice were treated with PBS or WGP and 7 days later pancreatic cells were
processed and restimulated with the supernatant from cultured (A) KPC or (B) Pan02
pancreatic cancer cells. Data are represented as mean ± SEM. ns= non-significant; *p <.05,
**p <.01, ***p <.001
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Figure 4.4: MIF secreted by tumor cells elicits the trained response
(A) The amount of rMIF in the supernatant from cultured untreated WT pancreatic cells,
KPC cells and Pan02 cells was measured using an ELISA. (B) WT mice were treated with
PBS or WGP and 7 days later pancreatic cells were processed and restimulated with 10
ng/mL of rMIF. Data are represented as mean ± SEM. ns= non-significant; *p <.05
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Figure 4.5: Recombinant HMGB1 elicits the trained response
WT mice were treated with PBS or WGP and 7 days later pancreatic cells were processed
and restimulated with 10 ng/mL of mouse HMGB1. Data are represented as mean ± SEM.
ns= non-significant; **p <.01
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Figure 4.6: WGP treatment positively regulates genes realtedto phagocytic cellular
processes
Enrichment plots (GSEA) and heat map of genes related to the positive regulation of
phagocytosis in CD11b+ cells from 7-day WGP-trained as compared to PBS mice
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Figure 4.7: WGP training increases phagocytosis of a pHrodo Green Staph Aureus
particle
(A) The percent of CD45+ pancreatic cells that phagocytosed a pHrodo Green Staph Aureus
particle in PBS and 7-day WGP mice along with the MFI of the pHrodo Green Staph
Aureus particle. (B) The percent of CD11b+ myeloid pancreatic cells that phagocytosed a
pHrodo Green Staph Aureus particle in PBS and 7-day WGP mice. Cells were first gated
on the CD45+ population. The MFI of the pHrodo Green Staph Aureus particle is shown.
Data are represented as mean ± SEM. *p <.05, **p <.01, ***p <.001, ****p <.0001
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Figure 4.8: WGP training increases phagocytosis of KPC tumor cells
The percent of CD11b+ myeloid pancreatic cells that phagocytosed KPCGFP+ tumor cells in
PBS and 7-day WGP mice. Cells were first gated on the CD45+ population. The MFI of
the GFP+ signal is shown. Data are represented as mean ± SEM. *p <..01
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Figure 4.9: WGP treatment enhances cytotoxicity of myeloid cells against tumor cells
(A) Enrichment plots (GSEA) and heat map of genes related to the reactive oxygen species
biosynthetic processes and the positive regulation of reactive oxygen species metabolic
processes in CD11b+ cells from 7-day WGP-trained as compared to PBS mice. (B)
Summarized results from a cytotoxicity assay where CD11b+ cells from PBS and 7-day
WGP-trained mice were sorted and incubated at a ratio of 1:20 KPCLuc+: CD11b+ cells for
24 hours. NAC was used to block ROS expression and the tumor cytotoxicity was assessed
by measuring luminescence (PBS n=3, WGP n=4). Data are represented as mean ± SEM.
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Figure 4.10: WGP treatment decreases tumor size in an orthotopic model of
pancreatic cancer
(A) Experimental schema. (B) C57BL/6 mice received a single IP injection of WGP or
PBS and 7 days mice were implanted orthotopically with KPC pancreatic cancer cells.
Representative pictures of tumors and quantitative analysis of tumor weight are shown.
Tumor weight was measured at day 21 (PBS n=5, WGP n=5). (C) C57BL/6 mice received
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size in vivo. Data are represented as mean ± SEM. *p <.05, **p <.01, ***p <.001
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Figure 4.11: Immune phenotyping of PBS vs WGP treated pancreatic KPC tumors
(A) Phenotyping of the tumors showing the percent of viable cells that are CD45+, the
percent of the CD45+ population that are CD11b+, and the percent of CD11b+ cells that are
F4/80+. (B) TNF production in CD11b+ cells from PBS and 7-day WGP-trained that were
restimulated with LPS. Percent of TNF+ cells and the MFI of TNF are shown. (C)
Summarized data of TNF production in CD11b+F4/80+ cells from PBS and 7-day WGPtrained that were restimulated with LPS. Percent of TNF+ cells and the MFI of TNF are
shown. (D) Tumor weight was correlated with the percent of CD45+ immune cells that were
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CD11b+ (left) and the percent of CD45+CD11b+TNF+ cells (right). (E) Summarized data
of the percent of CD4+ and CD8+ T-Cells expressing IFN. Data are represented as mean
± SEM. Pearson correlation coefficients were used to measure the strength of the linear
associations. *p <.05, **p <.01, ***p <.001.
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Figure 4.12: Additional tumor models to test the anti-tumor effects of WGP
(A) C57BL/6 mice received a single i.p. injection of WGP or PBS and 7 days mice were
implanted orthotopically with Pan02 pancreatic cancer cells. Representative pictures of
tumors and quantitative analysis of tumor weight are shown. Tumor weight was recorded
at day 21 (PBS n=5, WGP n=5). (B) NSG mice were treated with either PBS or WGP and
7 days later orthotopic KPC pancreatic tumors were implanted. 21 days following tumor
implantation, mice were euthanized and tumor weight was recorded. Data are represented
as mean ± SEM. *p <.05, P**<.01.
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Figure 4.13: Neutrophils are not involved in the anti-tumor effects of WGP
(A+B) To deplete neutrophils, mice were treated with anti-Ly6G mAb or anti-rat IgG2a
isoype control on day -2. On day 0 mice were treated with PBS or WGP and on day 7 mice
were implanted with orthotopic KPC pancreatic tumors. Additional doses of the anti-Ly6G
mAb or anti-rat IgG2a isoype control were given on days 4, 10 and 16 to maintain the
Ly6G depletion. On day 21, mice were euthanized and (A) the depletion efficiency was
assessed and (B) tumor weight was measured. Data are represented as mean ± SEM. **p
<.01, ***p <.001.
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Figure 4.14: WGP does not reduce tumor burden in CCR2-/- mice
C57BL/6 were treated with PBS or WGP and CCR2-/- mice were treated with WGP and 7
days later were implanted with orthotopic KPC pancreatic tumor cells. Tumor weight and
size was monitored for 3 weeks after implantation and tumor weight at day 21 is reported.
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Figure 4.15: CCR2+ and CCR2- admix tumor model
WT mice were treated with WGP and 7 days later the CD11b+ and CD11b- populations
were sorted, mixed with KPC tumor cells and implanted orthotopically into WT mice. 21
days after tumor implantation, mice were euthanized and tumor size was measured.
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(CCR2+ n=5, CCR2- n=5). Data are represented as mean ± SEM. ns= non-significant; *p
<.05
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Figure 4.17: Bone marrow chimera model to assess the role of central trained
immunity in orthotopic pancreatic tumors
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B6/SJL (CD45.1) mice were treated with PBS or WGP and 7 days later 2x106 BM cells
were transplanted into lethally irradiated WT (CD45.2) mice. 6 weeks after transplantation,
recipient mice were implanted with orthotopic KPC tumors and tumor size was evaluated
14 days later (PBS n=6, WGP n=6) Data are represented as mean ± SEM. ns= nonsignificant.
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Figure 4.18: WGP synergizes with anti-PD-L1 immunotherapy to prolong survival
(A) scRNA-Seq data showing a UMAP of the myeloid clusters expressing CD274. (B)
Experimental schema of WGP and anti PD-L1 therapy. Mice (n=5) were treated with PBS
or WGP and 7 days later were implanted with orthotopic KPC pancreatic tumors. On days
3,7 and 11 post-tumor implantation, mice were given anti-PD-L1 mAb or anti-rat IgG2b
mAb isotype control. Survival of mice was monitored.**p <.01, ****P<.0001
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Experimental schema of WGP used in the therapeutic setting. Mice were implanted with
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CHAPTER IV DISCUSSION
As we show that peripheral trained immunity has been established in the pancreas, an
important question is whether this nonspecific innate immunological memory could be
reactivated by tumor cells or their secreted factors. Re-exposure of in vivo WGP-trained
pancreatic myeloid cells to tumor conditioned media vigorously elicits a potent trained
response. While Kalafati et al recently showed a role for granulocytes in trained immunity
driven anti-tumor mechanisms [203], the currently reported study is the first instance
suggesting that myeloid cells in a specific organ can be trained to react directly to tumor
cells of that same organ. Further, while we highlight that tumor-conditioned media can reactivate trained myeloid cells, we also identify specific factors in the tumor-conditioned
media that are involved in this activation. MIF, which is known to be primarily secreted by
tumor cells and whose primary targets are myeloid cells [205, 206], was found to be
actively secreted by both Pan02 and KPC tumor cells. Using this average concentration of
rMIF to re-stimulate WGP-trained cells showed that MIF can activate trained myeloid
cells. We also show that HMGB1 can elicit the trained response. Others have reported that
DAMPs can be involved in trained immunity, however have primarily shown that they can
act as the initial training stimulus [207]. It has not been previously shown that DAMPs
secreted by tumor cells can re-stimulate trained cells. This understanding has implications
for which cancer cell types may be most capable of re-stimulating trained cells based on
the DAMPs that that cell type secretes. Furthermore, there are likely other tumor-secreted
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factors that may also function to re-activate trained myeloid cells and may activate them to
different extents, and further investigation into these specific factors may shed more light
on the anti-tumor capabilities and mechanisms of trained immunity. Ultimately, we also
identify the novel concept that specific factors released by tumors and tumor cells
themselves can act as the second signal in the incitement of trained immunity.
While often the anti-tumor mechanisms of myeloid cells are thought to be indirect and
orchestrated through the activation of adaptive immune cells, here we show that WGP
training upregulates the direct anti-tumor functionalities of myeloid cells in the pancreas.
Due to WGP training we observed enhanced phagocytosis of tumor cells and ROS
mediated cytotoxicity to tumor cells. Inhibiting ROS production abrogates the cytotoxicity
of WGP-trained myeloid cells. Supporting results of the cytotoxicity assay, CyTOF data,
RNA-Seq data and scRNA-Seq data all identify substantial enhancements in the expression
of ROS-related molecules/genes in these trained cells, though other groups have submitted
that training by -glucan is not associated with increased production of ROS by
macrophages/monocytes [125, 208]. This finding suggests that the phenotype of trained
immunity induced by particulate -glucan in the pancreas may be unique. Supporting our
results, several studies have characterized the mechanism of BCG-trained macrophages
cytotoxicity against bladder cancer cells. Such studies indicate that the cytotoxic effects
are due to both enhanced cytokine production and the production of ROS [209-211]. It is
also worth noting that while our findings show that ROS production is an important
contributor to the anti-tumor phenotype, in the complex tumor setting there are likely
additional pathways that play a significant role in the tumor surveillance and control
performed by trained myeloid cells.
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We then translate our findings regarding the anti-tumor potential of the trained innate
myeloid cells that enter the pancreas to orthotopic models of pancreatic cancer, where we
observe a dramatic decrease in the tumor size and an increase in the survival of mice given
only one I.P administration of WGP. We also observe a reduction of tumor size in mice
with both KPC and Pan02 tumors, revealing that these myeloid-driven anti-neoplastic
effects are broadly applicable to pancreatic tumors. Importantly, through the depletion of
neutrophils, along with the use of NSG mice and CCR2-/- mice, we demonstrate that the
cells responsible for tumor control are innate myeloid-derived cells that traffic to the
pancreas through CCL2-CCR2 signaling.
BM chimeric models support that the presence of trained immunity within HSCs in the
bone marrow is not enough on its own to slow the growth of pancreatic tumors, which is
in contrast to other proposed models of peripheral trained immunity. Instead, the early
trafficking of WGP to the pancreas and the resulting production of CCL2 by cells in the
pancreas recruit trained CCR2+ myeloid cells from the circulation and periphery, which
contribute to the antitumor effects. It is important to point out that given how quickly
trained immune cells arrive in the pancreas, it is unlikely that these cells are directly from
the bone marrow, though further investigations are needed to ascertain the source of
incoming trained myeloid cells.

We also show that several new populations of

macrophages and monocytes exist in the pancreas following WGP training, all of which
display features of trained immunity. It is thus likely the case that in this model there is not
a single cell type that is responsible for the slowed tumor growth, but rather the result of a
juxtaposition of an increase in pro-inflammatory trained cells and a decrease in the number
and function of resident pro-tumorigenic cells.
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It has been noted by several studies that the CCR2+ present within a tumor have protumorigenic roles [212, 213]. In pancreatic cancer, CCL2 production results in the
mobilization of CCR2+ inflammatory monocytes from the bone marrow to the tumor,
where they become TAMs [214]. For this reason CCR2 inhibitors used in combination
with chemotherapy for PDAC have been tested, and ultimately demonstrated a more
favorable response than chemotherapy used alone [215]. In contrast to these studies, here
we demonstrate that CCR2+ cells recruited to the tumor have anti-tumor potential due to
the fact that they have been trained by WGP. Unlike typical CCR2+ cells recruited to the
TME, in this model CCR2+ cells recruited to the tumor site have undergone transcriptional
and metabolic reprogramming that allows them to exert anti-tumor properties within the
TME. A major downfall of the use of therapeutic use of CCR2 inhibitors is that the
depletion of TAMs often results in a compensatory influx of tumor associated neutrophils
(TANs) to the TME which themselves have many pro-tumorigenic roles. Therefore instead
of using CCR2 inhibitors in the setting of PDAC, it may be more reasonable to consider
therapies that reprogram CCR2+ cells that will traffic to the tumor anyways to have antitumor functionalities [216].
We note high expression of MHC II on trained monocyte/macrophages in the pancreas,
which likely play a role in tumor antigen processing and communication with T-cells to
elicit adaptive immune responses against the tumor. While based on NSG tumor studies,
these antitumor mechanisms do not depend on adaptive immune responses, it is
conceivable that activated myeloid cells could exert a positive influence on adaptive
immune cells to aid in the generation and activation of tumor-specific T-cells and in antitumor adaptive responses. Specifically in the treatment setting where myeloid cells will
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traffic to the pancreas which bears a tumor already, the arrival of activated myeloid cells
expressing high levels of MHCII could play an important role in taking up and presenting
antigen to T-cells. This could result in an enhanced generation of tumor-specific T-cells
that could exert important anti-tumor effects. Accordingly, models where WGP is
administered before the tumor is implanted versus after the tumor is implanted may show
different types of T-cell responses. While this project focuses primarily on the role of
trained innate myeloid cells and their direct anti-tumor effects, more investigations on the
consequences of trained innate immunity on anti-tumor T-cell responses is warranted. It
may also be important to determine if alterations to the T-cell compartment due to WGP
treatment are responsible for the success of combination therapy of WGP and anti-PD-L1
therapy or if these effects are solely due to changes to the myeloid cells.
Another focus of future investigations is the optimization of WGP treatment in terms
of dosing and the number of treatments could further extend survival. While we did
observe a decrease in tumor size and longer survival due to WGP training, all mice did
eventually succumb to the tumor, even in combination with anti-PD-L1 therapy.
Immunosuppressive myeloid cells play a critical role in the creation of the hostile TME
in PDAC through the inhibition of T-cell effector function and the promotion of cancer
stemness, angiogenesis, stroma deposition, and metastasis formation [217-219]. While it
is the case that within the TME tumor secreted factors often reprogram myeloid cells to
propagate tumor growth, these cells also harbor the potential for robust anti-tumor
responses [220-222]. A conceivable reason why immunotherapy alone has yet to show
success in the treatment of PDAC is that these therapies have a primary objective of
reactivating tolerogenic T-cells rather than reactivating and reprogramming the
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suppressive myeloid cells that promote them. Accordingly, two therapeutic strategies that
could benefit PDAC patients but that have not yet been successfully implemented in a
clinical setting are therapeutics that 1) promote the reprogramming of immunosuppressive
myeloid cells in the PDAC TME, and 2) actively recruitment anti-tumor myeloid cells to
the tumor that can penetrate the desmoplastic stroma. Here, we demonstrate a novel
capability to engage both of these anti-tumor mechanisms in the setting of PDAC through
the induction of trained innate immunity in the pancreas by particulate

-glucan.

Importantly, we also show that the novel ability to initiate trained immunity in the pancreas
potentiates the therapeutic effects of immunotherapy such as anti-PD-L1 immunocheckpoint blockade therapy. Lending further clinical applicability to these findings, we
also exhibit that the induction of TI in the adjuvant setting can decrease tumor size and
prolong survival. These findings emphasize the potential of using -glucan to
therapeutically target myeloid cells within the TME and highlight that the induction of
peripheral trained immunity in the pancreas may have a consequential role in
reprogramming the suppressive TME of PDAC and in extending the life of patients
diagnosed with this deadly malignancy.
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SUMMARY AND FUTURE DIRECTIONS

Figure S1: Graphical Abstract
1) Mice are injected with IP WGP which traffics to the pancreas both in peritoneal
macrophages and as naked WGP. 2) M2 resident macrophages in the pancreas are
repolarized to an M1 phenotype after WGP trafficking and WGP also impacts peripheral
myeloid cells. All cells that come into contact with WGP become trained. The arrival of
WGP to the pancreas initiates the production of CCL2 and this signaling recruits CCR2+
trained myeloid cells from the periphery to the pancreas. 3) When trained cells in the
pancreas are reactivated by tumor cells and their supernatants, they will produce cytokines
and ROS in addition to initiating phagocytosis of tumor cells. Together these mechanisms
kill tumor cells and reduce tumor burden.
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The data presented in this dissertation reveal a novel trafficking mechanism of glucan to the pancreas that initiates a CCR2-dependent induction of peripheral trained
immunity and reprogramming of M2-like resident macrophages to M1-like. We show that
trained cells present in the pancreas following WGP treatment have significant anti-tumor
functionality, and that tumor cells and the soluble factors that they secrete can function as
a secondary stimulus to reactivate previously trained cells. Through models of orthotopic
pancreatic cancer we demonstrate that the induction of peripheral trained immunity in the
pancreas leads to an overall reduced tumor burden and longer survival (Fig S1).
We also illustrate that while immunotherapy alone fails to effectively reduce
pancreatic tumor burden, treatment with WGP synergizes with anti-PD-L1 mAb therapy
to further prolong survival. Finally, we show that WGP effectively reduces tumor burden
in the treatment setting. These findings have significant clinical relevance as innovative
strategies to effectively target and treat pancreatic cancer are desperately needed.
One potential challenge in the translation of these results to the clinical setting
comes from the intraperitoneal route of administration of the WGP. While more invasive
than intravenous or oral administration, IP injection is a commonly utilized clinical practice
in the treatment of a variety of malignancies including ovarian and mesenteric cancer [223225]. Importantly, the current standard of care for patients with pancreatic cancer often
necessitates a surgeon to gain access to the peritoneal cavity providing an opportunity to
deliver IP WGP without requiring additional surgical intervention. For example, a patient
diagnosed with stage I or II PDAC will usually receive a diagnostic laparoscopy one week
prior to final surgical resection followed by adjuvant chemotherapy. In this case, WGP
could be administered IP at either the time of the diagnostic laparoscopy or at the time of
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resection. In the case of a patient with locally advanced stage III disease, they will often
receive neoadjuvant FOLFIRINOX treatment followed by a diagnostic laparoscopy one
week prior to treatment with irreversible electroporation (IRE) [226, 227]. Both the
diagnostic laparoscopy and the IRE procedure would provide an opportunity to administer
IP WGP. At this time we are in the process of generating additional safety data that would
support the creation of a clinical trial. Additionally, we are investigating whether the IP
administration of WGP to pigs also results in an influx of trained innate immune cells to
the pancreas. Should these studies have positive results, future studies will aim to
investigate whether the administration of IP WGP may help in prolonging the survival of
human patients diagnosed with pancreatic cancer. These studies would involve
investigation into the ideal dose and timing of WGP administration, and would also detail
if WGP treatment synergizes with therapies such as IRE or immune-checkpoint blockade
therapy.
As checkpoint inhibitor monotherapy has failed to improve patient outcomes in the
setting of PDAC, none of these therapies are currently approved for use in PDAC patients
[6]. The highly immunosuppressive microenvironment of PDAC poses a significant
challenge to the efficacy of immunotherapies, as does the dense desmoplastic stroma and
infiltration of immunosuppressive myeloid cells. Our studies highlight that strategies to
reprogram the myeloid compartment within PDAC may prove to be effective in unleashing
the potential of immunotherapy. Thus, further investigations into the mechanisms that
allow WGP to synergize with anti PD-L1 therapy are needed as they may elucidate
important underlying mechanisms regarding resistance to immunotherapy that can be
applied widely and to other cancer types.
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As discussed earlier, the specific tropism of WGP to the pancreas is also a novel
finding and carries with it the potential to load WGP with other therapeutics such as
chemotherapy or siRNA and have them directly delivered to the pancreas. More studies
are certainly warranted to investigate why WGP shows specific tropism to the pancreas
and whether this phenomenon is based on an anatomical or chemical mechanism.
Additionally, while the induction of trained immunity in the pancreas was shown to directly
have anti-tumor effects, the delivery of cancer therapeutics directly to the pancreas in the
setting of PDAC provides a major challenge to its treatment. Further, systemic therapies
such as chemotherapy often result in high degrees of toxicity that contribute to patient
morbidity and mortality, and often do not effectively target the intended organ because of
altered vasculature due to angiogenesis. Hence future studies may focus entirely on how
this tropism of WGP to the pancreas can be manipulated to deliver effective doses of antitumor therapeutics. For example, WGP particles loaded with siRNA against PD-L1 could
traffic to the pancreas where they not only could induce peripheral trained immunity due
to the presence of WGP, but may also be taken up by resident macrophages and DCs in the
TME, which would result in decreased PD-L1 expression and enhanced T-cell activation
and killing of tumor cells (Fig S2).
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Figure S2: Schematic of the use of WGP particles loaded with anti-tumor agents to
target the pancreas

Finally, the induction of peripheral trained immunity in a visceral organ has not
been previously reported. Though peripheral trained immunity has been identified to exist,
how it is initiated in a specific organ has not been investigated before. This work identifies
that WGP arrival to the pancreas stimulates the production of CCL2 which likely plays a
major role in recruiting CCR2+ trained myeloid cells to the pancreas that can be
restimulated by tumor cells. We also assume that immunosuppressive resident
macrophages in the pancreas undergo repolarization due to the arrival of WGP to the
pancreas. It is possible that injection of WGP to a specific organ may also result in a similar
signaling mechanism that would result in anti-tumor effects, and so future studies are
needed to investigate whether the mechanism outlined in this paper is specific to the
pancreas or can be deployed to incite anti-tumor effects in other tumor-bearing locations
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METHODS
Mice:
Six to eight week-old female wild-type (WT) C57BL/6J mice were purchased from the
Jackson Laboratory (Bar Harbor, ME, USA) or bred in the University of Louisville specific
pathogen-free (SPF) animal facility. C57BL/6 Dectin-1 knockout (Dectin-1 -/-) mice were
described previously [228]. CCR2 global knock-out mice were purchased from Jackson
Laboratory. Albino C57BL/6 mice were kindly provided by Dr. Jonathan Warawa at the
University of Louisville. NOD/SCID/IL2rNull (NSG) mice and B6/SJL-CD45.1 were
purchased from the Jackson Laboratory. All mice were at least 6 weeks of age upon use,
and all experiments involving animals were performed in compliance with all relevant laws
and institutional guidelines provided by the Rodent Rearing Facility (RRF) and approved
by the Institutional Animal Care and Use Committee (IACUC) of the University of
Louisville.

Preparation of -glucan:
Highly purified particulate -glucan in the form of particulate Whole -glucan Particles
(WGP) isolated from Saccharomyces cerevisiae was provided by Biothera. Before use,
WGP was gently sonicated for 15 seconds, 2 times using a Qsonica Q55-110 Q55 Sonicator
(Cole-Parmer) to ensure aggregates were broken up.

Preparation and use of DTAF WGP:
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DTAF (Sigma Aldrich) at 2mg/mL was mixed with a suspension of 20mg/mL WGP in
borate buffer (pH 10.8). This incubated at room temperature for 8 hours with continuous
mixing. Following incubation, the WGP was centrifuged and washed with cold sterile
endotoxin-free DPBS (Sigma Aldrich) 5 times or until the supernatant no longer contained
visible DTAF. The concentration was adjusted to 10mg/mL in the endotoxin-free DPBS
for storage. 1mg of the DTAF WGP was injected IP into C57BL/6 and Dectin-1 -/- mice
and organs were harvested 3 days later.
Preparation of the 89Zr-WGP:
WGP (100 mg) was mixed with Deferoxamine-SCN (2.7 mg, in 0.8 ml DMSO) and
suspended in 10 ml sodium carbonate buffer (0.1 M, pH 9.4) overnight at room temperature
in the dark with gentle shaking. The Deferoxamine-labeled WGP was then washed with DI
water (10X 40 mL), and 30 mg of Deferoxamine-labeled WGP was mixed with 3 mCi
of 89Zr oxalate in 2 ml Tris•HCl buffer (0.5 M, pH 7.5), and then incubated at 37 oC for 60
min with shaking. The 89Zr-WGP was then centrifuged and washed with 3 ml of sterile
PBS. The radioactivity of 89Zr-WGP was measured by a dose calibrator and used for in
vitro and in vivo studies.

Biodistribution and PET/CT Scan using 89Zr-WGP
Positron Emission tomography (PET)/computed tomography (CT) imaging was conducted
in C57BL/6 and Dectin-1 -/- mice 48 hours after IP injection of 1mg of pure 89Zr-WGP
or injection of 1x106 peritoneal macrophages that had been co-cultured with 25g/ml of
89Zr-WGP for 2 hours and then gently washed to remove excess 89Zr-WGP. The mice
were scanned for 15 min with a Siemens R4 MicroPET and followed by 10 min of CT
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scan. Siemens IAW soft- ware was used for the acquisition and reconstruction of the PET
signal, and Siemens IRW software was used for merging and analyzing the imaging data.
At the end of the imaging study, mice were euthanized, and organs of interest were
harvested. For biodistribution, 50 uL of peripheral blood was collected using a retrobulbar
bleeding technique. The brain, heart, lungs, liver, spleen, kidneys, pancreas, large intestine,
small intestine, stomach, femur, a piece of skin from the flank of the mice and the rectus
femoris muscle were harvested, weighed, and placed in a 2470 Wizard automatic gamma
counter (PerkinElmer) in order to measure the radioactivity of each tissue. The CPM values
were calculated using Prism software (GraphPad Software, La Jolla, CA).

Pancreatic processing
Following euthanization, mouse pancreas were harvested and gently cut into smaller pieces
using sterile scissors. They were suspended in a 15mL tube in complete media (RPMI)
with

1X

digestion

buffer

comprised

of

300U/ml

collagenase I, 60

U/ml

Hyaluronidase, and 80 U/ml DNase (Sigma). These were placed in a rotating incubator at
37°C with 5% CO2 for 15-20 minutes. The digestion buffer was then quenched with ice
cold complete RPMI 1640 and washed. Cells were passed through a sterile nylon 40 µm
basket filter and small undigested pieces of tissue were smashed using a sterile syringe
stopper in order to generate a single-cell suspension. If an appreciable number of red blood
cells (RBCs) were seen to exist in the sample, RBC lysis was performed by adding 2mL of
sterile 10x ACK (Thermo Fisher Scientific).

In vivo WGP administration
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Mice were given a single 1 mg intraperitoneal dose of gently sonicated WGP, 3 μm
polystyrene beads (Sigma Aldrich), or 3 μm fluorescent microspheres (Polysciences) (all
1mg in 200 l of sterile PBS) or 200 l of sterile PBS on day 0. For typical trained
immunity studies, 7 days following the initial IP dose, mice were euthanized using CO2
and the pancreas along with other tissues of interest were removed and processed. For dose
titration studies, .5mg, 1mg and 2mg of WGP were delivered IP in 200uL of sterile PBS.
For time titration studies, mice were injected with 1mg of WGP and the pancreas was
harvested after 24 hours, 48 hours, 3, 7, 10, 16 and 30 days later.

Ex vivo re-stimulation
In order to assess the trained phenotype of mononuclear cells in mice treated with WGP or
PBS ex vivo, after processing the pancreas, pancreatic cell suspensions were plated in 24
well plates and stimulated with LPS (10ng/ml), the supernatant from cultured KPC and
Pan02 cells (40%), and recombinant MIF (rMIF)(10ng/ml). rMIF was a generous gift
from Dr. Robert Mitchell at the University of Louisville and was prokaryotically expressed,
purified, and re-folded a described previously[229]. Cells were cultured in DMEM, and
incubated at 37C with 5% CO2 for 5-6 hours in the presence of 1X brefeldin A
(Biolegend). The cells were then harvested using a cell scrapper, washed, pelleted and then
stained for intracellular cytokine expression.

In vitro training and re-stimulation assay
Peritoneal macrophages or sorted CD11b+ cells from a mouse pancreas were plated in a
24 well plate for 2 hours at 37C and 5% CO2 to allow for the attachment of cells to the
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plates, after which the floating cells were gently aspirated. Attached cells were gently
washed with sterile PBS and then resuspended in 1mL of DMEM constituted of 10% FBS
1% penicillin/streptomcymin. For the initial training of cells, 25g/ml of particulate WGP,
25g/ml of 3m polystyrene microparticle beads (Sigma-Aldrich) or 100 uL of PBS were
added to the appropriate well and incubated for 24 hours. After 24 hours, wells were gently
washed to remove the initial stimulus and fresh DMEM was added and cells were incubated
with 5% CO2 at 37C for 7 days. After 7 days, the media was aspirated, replaced with fresh
media, and cells were re-stimulated with LPS (100ng/mL), the supernatant of KPC or
Pan02 cells (40%), or PBS as a control. 24 hours after stimulation, the supernatants were
harvested and used in an ELISA for TNF- and IL-6.

Tumor conditioned media
1x106 KPC or Pan02 cells were cultured in a six well plate in 4mL of complete DMEM
and at 37C and 5% CO2. After 3 days the supernatants were harvested and stored at -80C
in aliquots for use as tumor-conditioned medium. As a control, the pancreas of a C57BL/6
mouse was processed into a single cell suspension and 1x106 of these cells were cultured
in a six well plate in 4mL of complete DMEM and at 37C and 5% CO2, and supernatants
were also collected after 3 days.

Acquisition of peritoneal macrophages
Mice were euthanized and 5mL of sterile RPMI was injected into the peritoneum using a
25-gague syringe. The abdomen was massaged to liberate the peritoneal macrophages. A
small incision was made and a transfer pipette was used to remove the suspension. The

119

peritoneal cavity was then washed several times with cold RPMI and cells were pelleted at
1600 RPM.

Confocal Microscopy
Mice were injected IP with 1mg of DTAF-WGP and 4 hours later mice were euthanized
and peritoneal macrophages were harvested. Cells were suspended in 200 uL of sterile PBS
and were spun onto a microscope slide using a Shandon CytoSpin3 (Thermo Fisher). Slides
were then air dried for 10 min prior to staining. Cells were fixed with 4% formalin for 30
minutes, washed with PBS, washed again with a .3% triton solution, and then incubated
with blocking solution (20% FBS, .3% TritonX) for 1 hours. Cells were then washed and
incubated with F4/80 primary antibody overnight. Wells were washed and cells were
incubated with DAPI for 10 minutes. Slides were washed, a cover slip was applied to all
samples and images were acquired using a Nikon confocal microscope.

Flow cytometry
Single-cell suspensions in PBS with 1% FBS were blocked with murine Fc Block (antiCD16/CD32) at 4C for 15 minutes. Fluorochrome labeled antibodies for viability
(APC/Cy7) and to surface markers CD45, CD11b, F4/80, Ly6G, Ly6C, MHCII, CD3,CD4,
CD8, NK1.1, Ki67 (Biolegend) and CCR2 (R&D Systems) were used. After 30 minutes of
incubating in the dark at 4C, cells were washed with cold PBS, and filtered through a 40
µm mesh filter. The samples were acquired using a FACSCanto II cytometer (BD
Biosciences) and analyzed using FlowJo software (Tree Star, Ashland, OR).
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Intracellular staining for expression of cytokines
Following stimulation, cells were stained for the desired surface markers as described
above. The cells were then washed with cold PBS, and 500l of fixation buffer (Biolegend)
was added to the tubes, briefly vortexed and incubated in the dark at room temperature for
20 minutes. 1ml of Permeabilization buffer (Biolegend) was then added and samples were
centrifuged at 1600rpm for 5 minutes at 4C followed by one more wash using 1ml of
permeabilization buffer. Cells were resuspended in 200 l of permeabilization buffer and
cells were stained with antibodies against TNF-, Ki67, Granzyme-B, IL-12, IL-6 and
IFN or the respective isotype control overnight at 4C. Cells were then washed, filtered
and data was acquired using a flow cytometer.

FACS isolation of CD11b+ macrophages for in vitro training
The pancreas was processed into a single cell suspension as described above. Cells were
washed with 1 mL of PBS, incubated with Fc block for 10 minutes at 4C followed by
staining with viability dye (APC-Cy7), CD45 (PerCPcy5) and CD11b+ (APC) for 30
minutes at 4C. Cells were washed with PBS and re-suspended in cold MACS Running
Buffer (Miltenyi Biotech). Viability-CD45+CD11b+ cells were sorted using a FACS Aria
III (Bd Biosciences). Cells were collected in a 50% FBS,40% PBS, 10% HEPES (Corning).
After sorting the cells were washed with PBS and then plated for in-vitro training, as
described above.

ELISA
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Supernatants from in vitro trained cells along with standards were analyzed using murine
TNF- and IL-6 ELISA kits (BioLegend).

The assay was performed per the

manufacturer’s instructions and all conditions were performed in triplicates. An ELISA
kit for r-MIF (R and D systems) was also used according to the manufacturer’s instructions
in order to quantify r-MIF in Pan02 and KPC tumor conditioned media and the supernatant
from cultured untreated pancreatic cells.

qRT-PCR
After CD11b+ cells had been isolated from the mouse pancreas in WGP treated and
untreated mice, cells were saved in TRIzol. RNAs were isolated and reverse transcribed
using the TaqMan Reverse Transcription Reagents (qRT-PCR) amplification using the
BioRad MyiQ single color RT-PCR detection system. Briefly, cDNA was amplified in a
25uL reaction mixture consisting of SYBR Green PCR super-mix (BioRad), 100 ng of
complementary DNA template, and selected primers (200 nM) using the recommended
cycling conditions.

H+E
7 days following injection with PBS/microparticle beads or WGP, the pancreata were
harvested and fixed in 4% formalin for 1 week followed by embedding in paraffin
according to standard procedures. Paraffin embedded tissues were cut into 5mm thick
sections and strained with hematoxylin and eosin (H & E) for morphological analysis.

Serum amylase measurement
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Murine serum amylase was measured using the Amylase Activity Assay Kit (Millipore
Sigma) and was used according to the manufacturer’s instructions. In short, mice were
injected with WGP and 7 days later, blood was collected from mice using a retro-bulbar
bleeding technique. These samples were used to assay for serum amylase.

In vivo T-cell depletion
T-cells were depleted using an anti-CD4 mAb alone, anti-CD8 mAb alone or anti-CD4 and
anti-CD8 mAbs together. Antibodies were made in-house. In this depletion procedure,
mice were injected IP with WGP on day 1 and were also injected IP with 200 µg of the
mAbs at day 1 and day 4 during the treatment period. Mice were euthanized on day 7. (CD4 clone GK1.5, CD-8 clone 53-6.72). Depletion efficiency was confirmed on day 7.

In vivo NK cell depletion:
NK cells were depleted through the intraperitoneal injection of 100 µg of PK136 mAb
(Produced in the laboratory of Dr. Jun Yan at the University of Louisville) on days -1 and
5 during the treatment period. WGP was injected at day 0, and on day 7 animals were
euthanized and the depletion efficiency of NK cells was assessed by staining pancreatic
tissues for NK1.1.

Ly6G depletion
Neutrophils were depleted by injecting 300 µg of anti-Ly6G mAb (Bio X Cell) or isotype
control Rat IgG2a (Bio X Cell) at day -1, 2 and 6 during the course of treatment. 1mg of
WGP was injected IP on day 1. Mice were euthanized on day 7 and the pancreas was
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assessed for efficiency of depletion. In the tumor model mice were injected with 300 µg
of anti-Ly6G mAb or isotype control Rat IgG2a on day -2, 4, 10 and 16. Mice were given
WGP at day 0, and were implanted with orthotopic KPC pancreatic tumors on day 7. Mice
were euthanized on day 21 and pancreatic tissues were stained with Ly6G to assess
granulocyte depletion efficiency at that time.

CyTOF mass cytometry sample preparation
Mass cytometry antibodies were either purchased from Fluidigm or were created in house
by conjugating commercially available purified antibodies to the appropriate metal isotope
using the MaxPar X8 Polymer or MCP9 Polymer kits (Fluidigm). Pancreatic samples from
three PBS and three 7-day WGP mice were processed into a single cell solution and exvivo stimulation was performed as described above. Cells were gently scraped from the
plates using a sterile cell scraper, washed with PBS and placed into a sterile culture tube.
2x106 cells per samples were used. Cells were first stained for viability with 5uM cisplatin
(Fluidigm) in serum free RPMI1640 for 5 minutes at RT. Cells were then washed with
RPMI1640 containing 10% FBS for 5 minutes at 300xg. Cells were stained with the surface
antibodies for 30 minutes at RT and washed twice with Maxpar Cell staining buffer
(Fluidigm). For staining on intracellular cytokines, cells were then fixed with 1 mL of 1X
Maxpar Fix I buffer for 30minutes at RT and then washed twice with 2 mL of 1X Maxpar
Perm-S buffer for 5 minutes at 800xg. The cytoplasmic/secreted antibody cocktail was then
added and incubated with the cells for 30 minutes at RT. Following incubation, cells were
washed with 1mL of 1X Maxpar Perm-S buffer for 5 minutes at 800xg and gently blotted
to remove all liquid from the tube. In order to stain for nuclear antigens cells were then
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suspended in 1 mL of 1X Maxpar nuclear antigen staining buffer for 30 minutes at RT.
The nuclear antigen antibody cocktail was then added and incubated for 30 minutes at RT.
Cells were washed with twice for 5 minutes at 800xg with 2mL of Nuclear Antigen
Staining Permeability buffer. Finally, cells were fixed with 1.6% formaldehyde for 10
minutes at RT, then incubated overnight in 125nM of Intercalator-Iridium (Fluidigm) at
4C.

CyTOF data acquisition
Once cells were ready for acquisition, samples were washed twice with Cell Staining
Buffer (Fluidigm) and kept on ice while awaiting acquisition. Directly prior to acquisition,
cells were suspended in a 1:9 solution of Cell Acquisition Solution: EQ 4 element
calibration beads (Fluidigm). A Helios CyTOF system was used, and following proper
startup and tuning procedures, samples were run at a rate of less than or equal to 500 events
/ second up to 300,000 events. Using the CyTOF software, .FCS files were normalized
into .fcs files, and these files were then ready to for data analysis.

CyTOF data analysis
CyTOF data was analyzed using FlowJo, the CytoBank software package [230], and the
CyTOF workflow [231] which includes a suite of packages available in R (rproject.org)[232-235]. For analysis conducted within the CyTOF workflow, FlowJo
workspace files exported from flow Workspace and CytoML were used [233].

RNA sequencing: RNA extraction and isolation
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7 days following administration of PBS or WGP IP, pancreata from were harvested,
processed into a single cell suspension as described previously, stained for viability, CD45
and CD11b as described previously, and sorted using a FACS Aria III as described
previously. Samples were prepared in triplicate for each experimental group. Once these
myeloid cells were isolated, cells were washed 2x with ice cold PBS and then lysed with
Trizol (Invitrogen). RNAs were extracted using a QIAGEN RNAeasy Kit (QIAGEN). The
isolated RNA was checked for integrity using the Agilent Bioanalyzer 2100 system
(Agilent Technologies, Santa Clara, CA) and quantified using a Qubit fluorometric assay
(Thermo Fisher Scientific, Waltham, MA). Poly-A enriched mRNASeq libraries were
prepared following the Universal Plus mRNA-Seq kit standard protocol (Tecan Genomics,
Redwood City, CA) using 10 ng of total RNA. All samples were ligated with Illumina
adapters and individually barcoded. Absence of adapter dimers and consistent library size
of approx. 300 bp was confirmed using the Agilent Bioanalyzer 2100. The library
concentration and sequencing behavior was assessed in relation to a standardized spike-in
of PhIX using a Nano MiSeq sequencing flow cell from Illumina. 1.8 pM of the pooled
libraries with 1% PhiX spike-in was loaded on one NextSeq 500/550 75 cycle High Output
Kit

v2

sequencing

flow

cell

and

sequenced on

the Illumina

NextSeq

500

sequencer targeting 60M 1x75bp reads per sample.

RNA sequencing
Libraries were prepared using the Universal Plus mRNA-seq kit with with NuQuant®
library quantification (NuGen). The six samples were spread across four sequencing lines
in one run. The 24 single-end raw sequencing files (.fastq) [236] were downloaded from
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Illumina’s BaseSpace [237] (https://basespace.illumina.com/) onto the KBRIN server for
analysis. Quality control (QC) of the raw sequence data was performed using FastQC
(version 0.10.1) [238]. The sequences were aligned to the mm10 mouse reference genome
using STAR (version 2.6) [239], generating alignment files in bam format. Differential
expression of ENSEMBL protein-coding transcripts was performed using DESeq2 [240,
241]. Raw counts were obtained from the STAR aligned bam format files using HTSeq
(version 0.10.0) [242]. The raw counts were normalized using the Relative Log Expression
(RLE) method and then filtered to exclude genes with fewer than 10 counts across the
samples [243].

RNA sequencing: Gene Set Enrichment Analysis
Gene set enrichment analysis (GSEA) was used to further characterize the biology of the
genes comprising the WGP vs PBS conditions and their differences [244]. Gene sets were
obtained from the Molecular Signatures Database (MSigDB) for Gene Ontology (GO)
biological processes and reactome pathways. For each gene set, all tested gene locations in
the comparison of WGP vs PBS treated control mice were sorted from highest to lowest
significance using p values. This approach allows highly significant up- and downregulated genes to be included within each gene set, an approach that more accurately
reflects the conditions in a biological pathway. For this analysis, a table of the enriched
sets is followed by an enrichment plot displaying the profile of the enrichment score (ES)
score and position of gene set members on the rank ordered list.

Single-cell sequencing: Isolation of single cells and RNA sequencing
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Live CD45+ cells were sorted from mouse pancreata, washed and resuspended in 1x PBS
(calcium and magnesium free) containing 0.04% BSA. Single cells were captured and
barcoded cDNA libraries were constructed using the Chromium Next GEM Single Cell 3ʹ
Reagent Kit (v3.1, 10X Genomics) and the Chromium Controller, according to
manufacturer’s instructions. Libraries were pooled and sequenced using a 28bp x 8bp x
125bp configuration for read1 x i7 index x read2 on the Illumina NextSeq 500 with the
NextSeq 500/550 150 cycle High Output Kit v2.5 (20024907).

Since cell sequencing: Gene expression profiling
Bcl files were demultiplexed into fastq files using the CellRanger software (10X Genomics,
v3.1.0). The total number of sequenced reads was 506,913,062. The reads were of good
quality as determined by FastQC [245]. Gene counts were measured using CellRanger
‘count’, utilizing the cellranger-mm10-3.0.0 reference genome for mouse. A counts matrix
was generated for each individual sample and one aggregated sample with the expected
number of cells set at 5,000.

The raw count data determined by CellRanger was used as input to a custom analysis
pipeline in R which uses a variety of single-cell analysis tools based on Seurat. The knee
plot (Fig S7B) displays a graph showing the ranked UMI counts for each cell barcode for
data aggregated across the three groups. Cells above the inflection point represent possible
doublets while those below the knee represent background cells. Cell quality control
measures were analyzed using Seurat v3 [246], and cell barcodes with the following
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characteristics were removed from the analysis: low counts (possible background cells)
with an FDR cutoff of 0.01 from the DropletUtils [247] function ‘emptyDrops’, high counts
(possible doublet cells) with more counts than the knee plot inflection point, mitochondrial
content greater than 30% and ribosomal content greater than 40%. Gene (features) were
further filtered to remove retired gene identifiers, and genes that were not expressed in at
least two cells. See Figure M1 for the initial and filtered number of cell barcodes and genes.

A

B

Figure M1: scRNA-seq cell counts and Knee plot
(A) Initial and filtered number of cell barcodes and genes. (B) Ranking of call cells by
UMI count of PBS, WGP-3day and WGP-7day, aggregated. Each curve has an associated
knee and inflection point, which indicates the likely range of true singlet droplet cells.
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The expression data was normalized using SCTransform [248] where cell cycle genes,
ribosomal content, and mitochondrial content were regressed. The cells were then clustered
and dimension reduction was performed using UMAP [249]. Initial cluster names were
assigned using a modified GSVA [250, 251] enrichment score technique. For each of these
clusters, the top marker genes were identified. Differentially expressed genes comparing
each cluster to every other cluster (all pairwise comparisons) was determined using Seurat
[246] and MAST [252].

Identification of clusters generated with scRNA-Seq
Non myeloid-derived clusters were classified generally as B-cells (MS4A1), plasma cells
(SDC1), CD8+ T-cells (CD3e, C8a), CD4+ T-cells (CD3e, CD4),T-regulatory cells (Tregs) (CD3e, CD4, FoxP3),  T-cells (CD3e, TRGC1, TRGC2,IL7Ra) and, type 2 innate
immune cells (ILC2s) (Alox5, KLRG1, Ly6a, Pparg,GATA3, IL-5, IL-13, and Rxrg) [253255]. Neutrophils were identified through MMP9, Csf3r, S100A8, S100A8 and ADAM8
expression, though may be underrepresented in these analyses due to their low RNA
content and high levels of intrinsic RNases [256]. Conventional dendritic cells (cDCs)
were identified through ITGAX and ITGAE expression and plasmacytoid DCs (pDCs) were
identified by ITGAX and Siglech.

Phagocytosis assays
The pancreas of PBS/microparticle injected mice and in-vivo WGP-trained mice were
harvested 7 days after injection and processed as described previously into a single cell
suspension. 2x106 were washed with HEPES dilutes 50x in RPMI 1640 and then incubated
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in 100 L of this solution for 1 hour at 37C in order to activate the cells. The Invitrogen
pHrodoTM Green S. aureus BioParticlesTM Phagocytosis Kit for Flow cytometry (Thermo
Fisher Scientific) was used according to the manufacturer’s instructions. 100 L of the
reconstituted particles or 1x106 GFP+ KPC tumor cells were added to the activated
pancreatic cells and incubated for 1 hour at 37C. Samples were gently vortexed every 15
minutes. The reaction was stopped by added 1mL of cold PBS. Samples were incubated
with Fc Block for 10 minutes at 4C, stained for viability, CD45, CD11b and F4/80 for 30
minutes at 4C, and then analyzed using a BD FACSCanto. For analysis, after gating on
live cells and CD45, cells that fluoresced in the FITC channel were determined to be
phagocytic.

Cytotoxicity assay
The pancreas from WGP and PBS treated mice were harvested and the CD11b+
populations were isolated using magnetic CD11b+ MicroBeads (Miltenyi Biotec) and an
autoMACS Pro Separator (Miltenyi Biotec). Purified CD11b+ cells were then washed and
counted, and these were plated at a ratio of 1:20 tumor:effector cells in a 96 well plate. All
experimental samples were run in triplicate. After plating the CD11b+ cells, the ROS
inhibitor N-acetly-l-cysteine (NAC) (Sigma Aldrich) was added to one set of PBS and
WGP derived cells at 1 mM for 1 hour before the addition of 5000 luciferase expressing
KPC+ pancreatic tumor cells to all wells. After 24 hours, of co-culture, the plates were
centrifuged and 20 µL of the supernatant was mixed with 100 µL of the Luciferase Assay
Reagent (Promega). Luciferase activity measured in the supernatant correlated with tumor
cells that had been killed by the effector cells and was measured using a luminometer
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(Femtomaster FB 12, Zylux Corporation). The spontaneous luciferase signal from plated
tumor cells was subtracted from the measurement of the supernatant. Luciferase values
are represented as Relative Light Units (RLUs).

In vivo tumor models of pancreatic cancer
A KPC cell line on a C57BL/6 background derived from the LSL-KrasG12D/+; LSLTrp53R172H/+; Pdx1-Cre (KPC) mouse model was purchased from Ximbio. These and
Pan02 cells which were a generous gift from Dr. Yong Lu at Wake Forest University, were
used in an orthotopic model of pancreatic cancer. A KPC line transfected with GFP and
luciferase (KPCGFP+Luc+) were also a generous contribution from Dr. Michael Dwinell at
the Medical College of Wisconsin. These cells were used exclusively in albino C57BL/6
mice. For tumor implantation, mice were anesthetized using isoflurane, and the abdomen
of the mice were pepped with betadine and draped in a sterile fashion. A 2 cm midline
laparotomy was performed using aseptic technique with sterile instruments. Following
laparotomy, the pancreas and spleen were externalized. Tumor cells were suspended in ice
cold PBS and mixed in a 1:1 ratio with basement membrane matrix Matrigel (Corning).
0.1x106 tumor cells in 50uL of the PBS-matrigel solution were injected into the tail of the
pancreas using a 30-guage insulin syringe. The formation of a small bubble indicated
successful implantation. The peritoneum was closed using coated polyglycolic acid braided
absorbable 5/0 suture and the skin was closed using silk braided nonabsorbable 5/0 suture.
(CP Medical). Buprenorphine was administered for pain management up to 72 hours
following surgery and mice were monitored.
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In vivo imaging
Mice implanted orthotopically with GFP+ Luciferase+ KPC tumor cells were injected IP
with 150mg/kg of body weight at 100 µL of XenoLight D-Luciferin-K+ Salt
Bioluminescent Substrate (Perkin Elmer). After 10 minutes, mice were anesthetized with
isoflurane and placed inside of a Biospace Lab Photon Imager, which is a dedicated low
light level in vivo optical modality for bioluminescent and fluorescent imaging. Images of
mice were taken and used to measure tumor size and growth.

Generation of BM chimeras
To generate BM chimera, B6/SJL (CD45.1) mice were treated with IP PBS or WGP and 7
days later the BM was harvested. WT mice (CD45.2) were lethally irradiated (950 cGy)
and 2x106 CD45+ BM cells from the B6/SJL PBS or WGP treated mice were transplanted
IV. Six weeks later, the peripheral blood of recipients was analyzed to check the success
of the BM transplant, and mice were implanted with .1x105 KPC cells orthotopically. 14
days later mice were euthanized and tumor size was assessed.

Combination therapy with anti PD-L1 mAb
C57BL/6 mice were treated with WGP at day -7 and implanted with KPC orthotopic
pancreatic tumors on day 0. Mice were treated with 200 µg of anti-mouse anti-PD-L1
mAb(Bio X Cell) or Rat IgG2b isotype control (Bio X Cell) at day 3, 7 and 11. Mice were
then monitored for survival.

WGP in the treatment setting
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C57BL/6 mice were implanted with KPC orthotopic pancreatic tumors at day 0 and on day
4 and 11 mice were given 1mg of IP WGP or PBS. Mice were then monitored for survival.

Statistical analysis
Results are represented as mean ± SEM. Data were analyzed using a two-tailed Student’s
t test or Mann-Whitney U-test. Multiple-group comparisons were performed using a oneway or two-way ANOVA followed by Tukey’s multiple comparisons test. Correlation
analyses were performed using Pearson correlation coefficient (normal distribution).
Statistical significance was set at p<.05. All statistical analyses were performed using
GraphPad Prism Software Version 9 (GraphPad Inc., La Jolla, CA).
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MATERIALS
REAGENT or RESOURCE
Antibodies
Viability Dye
Anti-mouse CD45, 30-F11

SOURCE
Invitrogen
BioLegend

IDENTIFIER

Ref #: 65-0865-14
Cat # 103129
RRID: Ab_893343
BioLegend
Cat # 101215
RRID:AB_312798
BioLegend
Cat # 123115
RRID: AB_893493
BioLegend
Cat # 100203
RRID:AB_312660
BioLegend
Cat # 100411
RRID:AB_312696
BioLegend
Cat # 100721
RRID:AB_312760
BioLegend
Cat # 115507
RRID:AB_313642
BioLegend
Cat # 108709
RRID:AB_313396
BioLegend
Cat # 128005
RRID:AB_1186134
BioLegend
Cat # 127607
RRID:AB_1186104
R&D Systems Cat # FAB5538P
RRID:AB_1071841
4
BioLegend
Cat # 506305
RRID:AB_315426
BioLegend
Cat # 505807
RRID:AB_315401
BioLegend
Cat # 400407
RRID:AB_326513
BioLegend
Cat # 400607
RRID:AB_326551
BioLegend
Cat # 100755
RRID:AB_2562796
BioLegend
Cat # 100345
RRID:AB_2563748

Anti-mouse CD11b, M1/70
Anti-mouse F4/80, BM8
Anti-mouse CD3, 17A2
Anti-mouse CD4, GK1.5
Anti-mouse CD8, 53-6.7
Anti-mouse CD19, 6D5
Anti-mouse NK1.1, PK136
Anti-mouse Ly6C, HK1.4
Anti-mouse Ly6G, 1A8
Anti-mouse CCR2, 475301

Anti-mouse TNF, MP6-XT22
Anti-mouse IFN, XMG1.2
Anti-Rat IgG1,  isotype, RTK2071
Anti-Rat IgG2b,  isotype, RTK4530
Anti-mouse CD8, 53-6.7
Anti-mouse CD3, 145-2C11
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Anti-mouse CD4, RM4-5

BioLegend

Anti-mouse CD11b, M1/70

BioLegend

Anti-mouse Ly6C, HK1.4

BioLegend

Anti-mouse CD19, 6D5

BioLegend

Anti-mouse IFN, XMG1.2

BioLegend

Anti-mouse IL-12/IL-35 p53, 27537

R+D Systems

Anti-mouse IL-17, TC11-18H10.1

BioLegend

Anti-mouse CCR2, 475301R
Anti-mouse Granzyme B, 12F9B65

R+D Systems
BioLegend

Anti-mouse TCR, GL3

BioLegend

Anti-mouse Tbet, 4B10

BioLegend

Anti-mouse CD107a, 1D4B

BioLegend

Anti-mouse TNF (141Pr), MP6-XT22
Anti-mouse CD11c (142 Nd), N418
Anti-mouse IL-2 (144Nd), JES6-5H4
Anti-mouse CD69 (145 Nd), H.2F3
Anti-mouse F4/80 (146 Nd), BM8
Anti-mouse CD44 (150Nd), IM7
Anti-mouse Ly-6G (151 Eu), IA8
Anti-mouse CD274 (PD-L1) (153 Eu),
10F.9G2
Anti-mouse FoxP3 (158 Gd), FJK-16S
Anti-mouse CD279 (PD-1) (159 Gd),
29F.1A12
Anti-mouse CD62L (L-Selectin) (160 Gd),
MEL-14
Anti-mouse iNOS (161Dy), CXNFT
Anti-mouse CX3CR1 (164DY), SA011F11
Anti-mouse IL-6 (167Er), MP5-20F3
Anti-mouse CD206 (169Tm), C089C3
Anti-mouse C161 (NK1.1)(170Er), PK136
Anti-mouse CD80 (171Yb), 16-10A1
Anti-mouse CD86 (172Yb), GL1
Anti-mouse CD223 (LAG-3) (174Yb),
C9B7W

Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm

Cat # 100561
RRID:AB_2562762
Cat # 101249
RRID:AB_2562797)
Cat # 128039
RRID:AB_2563783
Cat # 115547
RRID:AB_2562806
Cat # 505843
RRID:AB_2562847
Cat # MAB 1570
RRID:AB_2295829
Cat # 506935
RRID:AB_2562850
Cat # MAB55381R
Cat # 662801
RRID:AB_2564373
Cat # 118101
RRID:AB_313826
Cat # 644825
RRID:AB_2563788
Cat # 328635
RRID:AB_2563708
Product # 3141012B
Product # 3142003B
Product # 3144002B
Product #3145005B
Product #3146008B
Product #3150018B
Product #3151010B
Product #3153016B

Fluidigm
Fluidigm

Product #3165024A
Product #3159024B

Fluidigm

Product #3160008B

Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm

Product #3161011B
Product #3164023B
Product #3167003B
Product #3169021B
Product #3170002B
Product #3171008B
Product #3172016B
Product #3174019B
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Anti-mouse I-A/I-E (209Bi), M5/114.15
Anti-mouse CD45 (89Y), 30-F11
InVivoMAb anti-mouse Anti Ly6G, 1A8

Fluidigm
Fluidigm
Bio X Cell

Rat IgG2a Isotype Control, 2A3

Bio X Cell

InVivoMAb anti-mouse PD-L1(B7H1(10F.9G2)

Bio X Cell

Rat IgG2b Isotype Control (LTF-2)

Bio X cell

Made in the
Lab of Dr. Jun
Yan,
University of
Louisville
Anti Mouse anti CD4 mAb GK1.5
Made in the
Lab of Dr. Jun
Yan,
University of
Louisville
Anti Mouse anti CD8 mAb 53-6.72
Made in the
Lab of Dr. Jun
Yan,
University of
Louisville
Chemicals, Peptides, and Recombinant Proteins
Tris(2-carboxyethyl)phosphine
MilliporeSig
hydrochloride (TCEP) solution, pH 7.0
ma
(10x1mL, .5M)
HRP-protector peroxidase stabilizer
Boca
Scientific
Antibody Stabilizer PBS
Boca
Scientific
Sodium Azide, BioUltra, >99.5%(T)
MilliporeSig
ma
5-([4,6-Dichlorotriazin-2Sigmayl]amino)fluorescein hydrochloride
Aldrich
(DTAF )
ACK
Thermo
Fisher
Scientific
Brefeldin A
Biolegend
Collagenase I
Sigma
DNase
Sigma

Product #3209006B
Product #3089005B
BE0075-1
RRID:AB_1107721
BE0089
RRID:AB_1107769
BE0101
RRID:AB_1094907
3
BE0090
RRID:AB_1107780

Anti Mouse anti NK1.1 mAb PK136
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626547

222050
131050
71289
D0531

A1049201
420601
C9891
D5025

Endotoxin-free DPBS
Hyaluronidase
Matrigel® Basement Membrane Matrix,
LDEV-free, 5 mL
Ionomycin Calcium Salt
PMA
Fixation Buffer
Permeabilization buffer
Fluoresbrite® YG Microspheres,
Calibration Grade 3.00μm
3.00μm polystyrene Miroparticle
MACS Running Buffer
HEPES
TRIzol
Poly-L-Lysine
XenoLight D-Luciferin – K+ Salt
Bioluminescent Substrate
CD11b MicroBeads, Human and mouse
N-Acetyl-l-cysteine (NAC)
Lipopolysaccharides from E.coli0111:B4
.25% Trypsin 2.21 mM EDTA, 1x [-]
sodium bicarbonate
FBS
Bovine Serum Albumin Cohn Fraction V
Powder
Buprenorphine, hydrochloride, Injection

p-SCN-Bn-Deferoxamine
sodium carbonate
Oxalic acid, anhydrous
UltraPure™ 1 M Tris-HCI Buffer, pH 7.5

Zr-89 oxalate
Dulbecco’s Phosphate Buffered Saline
Chloroform
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SigmaAldrich
Sigma
Corning

TMS-012-A

SigmaAldrich
SigmaAldrich
BioLegend
BioLegend
Polysciences

I0634

SigmaAldrich
Miltenyi
Biotec
Corning
Invitrogen
Advanced
BioMatrix
Perkin Elmer

79166

Miltenyi
Biotec
SigmaAldrich
Sigma
Corning

130-049-601

Atlanta
Biologicals
Equitech0Bio,
Inc.
Par
Pharmaceutic
al
Macrocyclics
VWR
Sigma
Invitrogen
Washington
University at
St. Louis
Sigma
Sigma

Cat #: S11150

H2126
356234

79346
420801
421002
18861-1

130-091-221
25-060-CI
15596018
5048
12799

A7250-5G
L4391-1MG
25-053-Cl

Cat # BAC62-1000
Lot #171130-0262
10153802

B-705
BJ34277-1L
756888-50G
15567027
Radionuclide
Processing
Laboratory
D8537
C2432

2-propanol
UltaPureTM Glycogen
iScriptTM cDNA Synthesis Kit
iQTM SYBR® Green Supermix
RPMI-1640 medium
DMEM- high glucose
Critical Commercial Assays
MaxPar MCP9 Antibody Labeling Kit,
106Cd
MaxPar MCP9 Antibody Labeling Kit,
111Cd
MaxPar MCP9 Antibody Labeling Kit,
112Cd
MaxPar MCP9 Antibody Labeling Kit,
113Cd
MaxPar MCP9 Antibody Labeling Kit,
114Cd
MaxPar MCP9 Antibody Labeling Kit,
116Cd
MaxPar X8 Antibody Labeling Kit, 146Nd
MaxPar X8 Antibody Labeling Kit, 149 Sm
MaxPar X8 Antibody Labeling Kit, 154 Sm
MaxPar X8 Antibody Labeling Kit, 156 Gd
MaxPar X8 Antibody Labeling Kit, 162 Dy
MaxPar X8 Antibody Labeling Kit, 165 Ho
MaxPar X8 Antibody Labeling Kit, 166 Er
MaxPar X8 Antibody Labeling Kit, 168Er
MaxPar X8 Antibody Labeling Kit, 173Yb
ELISA MAXTM standard set Mouse TNF-
ELISA MAXTM standard set Mouse IL-6
Mouse MIF DuoSet ELISA
Invitrogen pHrodoTM Green S. aureus
BioParticlesTM Phagocytosis Kit for Flow
cytometry
Amylase Activity Assay Kit
QIAGEN RNAeasy Kit
Promega Luciferase Assay Systems
Luciferase Assay w/ Reporter Lysis buffer
Chromium Next GEM Single Cell 3ʹ GEM,
Library & Gel Bead Kit v3.1, 4 rxns
MiSeq Reagent Micro Kit V2 300 cycles
169

Fisher
Scientific
Thermo
Fisher
Scientific
BioRad
BioRad
Sigma
Sigma

A41701

Fluidigm

Cat # 201106A

Fluidigm

Cat # 201111A

Fluidigm

Cat # 201112A

Fluidigm

Cat # 201113A

Fluidigm

Cat # 201114A

Fluidigm

Cat # 201116A

Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
BioLegend
BioLegend
R&D Systems
Thermo
Fisher
Scientific

Cat # 201146A
Cat # 201149A
Cat # 201154A
Cat # 201156A
Cat # 201162A
Cat # 201165A
Cat # 201166A
Cat # 201168A
Cat # 201173A
430901
431301
DY1978
P535367

Millipore
Sigma
QIAGEN
Promega

MAK009

10X
Genomics
Illumina

10814010

1708891
1708880
R8758-1L
D5796-500ML

74104
E4030
PN-1000128
MS-102-2002

NextSeq 500 High Output Kit v2.5 (150
cycles)
Experimental Models: Cell Lines
KPC Cell Line
Pan02 Cell Line

KPC/FC1242 Luc/GFP clone 3

Illumina

20024907

Ximbio
Gift from Dr.
Yong Lu at
Wake Forest
University
Gift from Dr.
Michael
Dwinell, PhD
at the Medical
College of
Wisconsin

153474

Experimental Models: Organisms/Strains
Mouse: C57BL/6J
The Jackson
Laboratory
tm1Ifc
-/Mouse: B6.129S4-Ccr2
/J (CCR2 ) The Jackson
Laboratory
-/Mouse: Dectin-1
Mouse: NOD.CgThe Jackson
scid
tm1Wjl
Prkdc
Il2rg
/SzJ (NSG)
Laboratory
Mouse: B6(Cg)-Tyr c-2J /J (Albino
The Jackson
C57BL/6J mice)
Laboratory
Mouse: C57BL/6-CD45.1 B6.SJLThe Jackson
a
b
ptprc Pepc /BoyJ
Laboratory
Oligonucleotides
Primers for IL-6
Forward:
AAGACAAAGCCAGAGTCCTTCA
Reverse: AGAGCATTGGAAATTGGGGT
Primers for IL-10
Forward:
AGTGGAGCAGGTGAAGAGTG
Reverse: TTCGGAGAGAGGTACAAACG
Primers for iNOS
Forward:
GGTGAAGGGACTGAGCTGTTA
Reverse: CAACGTTCTCCGTTCTCTTGC
Primers for TNF-
Forward:
TGTAGCCCACGTCGTAGCAAA
Reverse:
GCTGGCACCACTAGTTGGTTGT
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000664
004999
(Saijo et al, 2007)
005557
000058
002014

Primers for CCL2:
Forward: GGTCCCTGTCATGCTTCTGG
Reverse: GCTGCTGGTGATCCTCTTGT
Software and Algorithms
CyTOF Workflow

Nowicka M.,
et al., 2019

https://f1000research
.com/articles/6748/v4

Prism 7

GraphPad

FlowJo v 10.7.1

TreeStar

https://www.graphpa
d.com/scientificsoftware/prism/
RRID: SCR_002798
https://www.flowjo.
com/
RRID: SCR_008520
http://www.bioinfor
matics.babraham.ac.
uk/projects/fastqc/
https://github.com/al
exdobin/STAR/
https://pypi.org/proje
ct/HTSeq/
https://bioconductor.
org/packages/release
/bioc/html/DESeq2.h
tml
https://www.gseamsigdb.org/gsea/ind
ex.jsp
https://support.10xge
nomics.com/
https://cloud.rproject.org/web/pack
ages/Seurat/index.ht
ml

Andrews,
2015

FastQC (v0.11.7)

HTSeq (v0.10.0)

Dobin et al.,
2013
Anders et al.,
2015

DESeq2 (v1.24.0)

Love et al.,
2014

STAR (v2.6)

Subramanian
et al., 2005
Zheng et al.,
2017

GSEA
CellRanger (v3.1.0)

Stuart et al.,
2019
Becht et al.,
2019

Seurat (v3.1.1)
UMAP

scater (v1.12.2)

McCarthy et
al., 2017

DropletUtils (v1.4.3)

Lun et al.,
2019
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https://bioconductor.
org/packages/release
/bioc/html/scater.ht
ml
https://bioconductor.
org/packages/release
/bioc/html/DropletUt
ils.html

Hafemeister
and Satija,
2019

sctransfrom (v0.2.0)

Finak et al.,
2015
MAST (v1.10.0)
Other
Amicon Ultra-.5 centrifugal Filter Unit,
.5mL V-bottom, 8-pack 3kDa
Amicon Ulrta-.5 centrifugal Filter Unit,
.5mL V-bottom, 8-pack 50 kDa
Amicon Ultra-.5 centrifugal Filter Unit,
.5mL V-bottom, 8-pack 100 kDa
Eppendorf protein LoBind Tubes, 1.5 mL
polyglycolic acid braided absorbable 5/0
suture
silk braided nonabsorbable 5/0 suture
40m Nylon, Sterile, DNase/RNase Free
Cell Strainers

172

https://github.com/C
hristophH/sctransfor
m
https://www.biocond
uctor.org/packages/r
elease/bioc/html/MA
ST.html

Millipore
Sigma
Millipore
Sigma
Millipore
Sigma
Eppendorf
CP Medical

UFC500308 (3 kDa)

CP Medical
VWR

682S
10199-655

UFC505008
UFC510008
0224431081
421A

CURRICULUM VITAE
NAME:

Anne Elena Geller

CONTACT:

University of Louisville School of Medicine
Clinical and Translational Research Building
505 S Hancock St
Suite 327 H
Louisville, KY 40204
412-215-1868 | Ageller17@gmail.com

DOB:

Pittsburgh, PA USA – November 6, 1991

EDUCATION
& TRAINING:

M.D.
University of Louisville School of Medicine
Louisville, KY USA
2015-present
Ph.D., Microbiology and Immunology
University of Louisville School of Medicine
Louisville, KY USA
2017-2021
Intramural Research Fellow
National Institutes of Health
Bethesda, MD USA
2014-2015
M.S., Biomedical Sciences
Tufts University
Medford, MA USA
2013-2014
B.S., Biomedical Science in Engineering
Minor in Engineering Entrepreneurship
University of Pennsylvania
Philadelphia, PA USA
2009-2013

173

AWARDS
& HONORS:

Graduate Dean’s Citation
“Awarded to one student from each department at
commencement in recognition of superior
accomplishment in their graduate studies”
University of Louisville, 2021
American Association of Immunologists Travel
Award Recipient to attend AAP/ASCI/APSA
Meeting
2020
Nominated and Inducted into the Honor Society of
Phi Kappa Phi for being in the top 10% of graduate
student’s GPA
2020
Research! Louisville Doctoral Basic Science
Graduate Student Award, 3rd Place
2018
Excellence in Bioengineering Senior Design
Competition Award, University of Pennsylvania
2013
University of Pennsylvania, Dean’s List
2011-2013
Pennsylvania Governor’s School for the Sciences
Scholar
2008

SCHOLARSHIPS
& FELLOWSHIPS

Integrated Programs in the Biomedical Sciences
(IPIBS) Graduate Fellowship
2017-2019
Summer Research Scholars Program (SRSP)
2015, 2016
Physician-Scientist Training Program (M.D./Ph.D)
Scholarship
2015-present
NIH Intramural Research Award Fellow

174

2014-2015
PROFESSIONAL
SOCIETIES:

American Association of Immunologists
Student Member
2019-present
American Physician Scientists Association
2015-present
Greater Louisville Medical Society
2015-present

LEADERSHIP &
VOLUNTEER WORK

University of Louisville School of Medicine
Strategic Planning Committee Member
2020
University of Louisville Faculty Forum Graduate
Student Representative
2017-Present
Curriculum Committee Student Representative
Department of Microbiology and Immunology
2017-2018
Class Treasurer for the Class of 2019 School of
Medicine
2015-2016
Class Representative for the Biochemistry Course
2015
Volunteer at the EMW Women’s Surgical Center
Louisville, KY USA
2015-present
Medical Student Volunteer at the GLOH and HOPE
community clinics
2015-2016

PUBLICATIONS: (*Co-first authorship)

Geller, A. and J. Yan, The Role of Membrane Bound Complement Regulatory Proteins

175

in Tumor Development and Cancer Immunotherapy. Frontiers in Immunology, 2019.
10(1074).
*Geller, A., *Shrestha R, Yan J. Yeast-Derived β-Glucan in Cancer: Novel Uses of a
Traditional Therapeutic. International Journal of Molecular Sciences. 2019; 20(15):3618.
Woeste, M. R., Bhutiani, N., Geller, A. E., Eldridge-Hindy, H., McMasters, K. M., &
Ajkay, N. (2020). Identifying Factors Predicting Prolonged Opioid Use After
Mastectomy. Ann Surg Oncol. doi: 10.1245/s10434-019-08171-4
Bridgewater C, Geller A, Hu X, Burlison JA, Zhang HG, Yan J, Guo H. 89Zr-Labeled
Anti-PD-L1 Antibody Fragment for Evaluating In Vivo PD-L1 Levels in Melanoma
Mouse Model. Cancer Biother Radiopharm. 2020 Oct;35(8):549-557. doi:
10.1089/cbr.2019.3056. Epub 2020 Apr 21.
Geller A, Yan J. Could the Induction of Trained Immunity by β-Glucan Serve as a
Defense Against COVID-19?. Front Immunol. 2020;11:1782. Published 2020 Jul 14.
doi:10.3389/fimmu.2020.01782
*Woeste, M.R., *Geller, A.E., Martin, R.C.G. et al. Optimizing the Combination of
Immunotherapy and Trans-Arterial Locoregional Therapy for Stages B and C
Hepatocellular Cancer. Ann Surg Oncol (2021).
*Morrissey, S.M.,*Geller, A.E. et al., Emergence of Low-density Inflammatory
Neutrophils Correlates with Hypercoagulable State and Disease Severity in COVID-19
Patients. medRxiv, 2020: p. 2020.05.22.20106724.
(Accepted at JCI Insight)
Geller AE, Shrestha R, Guo H, Chuanlin D, Woeste MR, Andreeva K, Chariker JH,
Zhou M, Tieri D, Watson CT, Mitchell R, Martin RCG, Rouchka EC, Yan J, The
Induction of Trained Immunity in the Pancreas Incites Anti-tumor Activity in Models of
Pancreatic Cancer (2021)
(Manuscript in preparation)
Noe JT, Rendon BE, Geller AE, Morrissey SM, Conroy LR, Kim EJ, Wise-Mitchell A,
Rizzo MBS, Young LE, Bruntz RC, Affronti HC, McMaster KM, Clem BF, Wellen KE,
Sun RC, Mitchell RA. Lactate Supports a Metabolic-Epigenetic Link in Macrophage
Polarization (2021)
(Manuscript in preparation)

176

Ding C, Shrestha R, Zhu X, Geller AE, Woeste MR, Li W, Yuan F, Chariker JL, Hu X,
Li H, Puckett A, Zhang H, Rouchka EC, Mitchell R, Siskind L, Zhang X, McMasters
KM, Yu Y, Yan J. Induction of Trained Immunity Controls Cancer Metastasis Through
the Sphingolipids-Mitochondrial Fission Pathway (2021)
(Manuscript currently under peer review)

ABSTRACT AND POSTER PRESENTATIONS:
A.E. Geller, H. Guo, C. Ding, J. Yan. “In Vitro and In Vivo Evaluation of Radiolabeled
Particulate ß-glucan.” Research Louisville, Louisville, KY. October 2016
A.E. Geller, H. Guo, C. Ding, J. Yan. “In Vitro and In Vivo Evaluation of Radiolabeled
Particulate ß -glucan.” Southeastern Medical Scientist Symposium, Atlanta, Georgia.
November 2017
H. Guo, A.E. Geller, J. Yan. “89Zr-Df-anti-PD-L1 for evaluating in vivo PD-L1 levels in
mouse models lung cancer.” Society of Nuclear Medicine and Molecular Imaging.
Anaheim, California. June, 2018
A.E. Geller, H. Guo, C. Ding, J. Yan. “The characterization of ß -glucan’s mechanism of
action as an anti-cancer therapeutic.” Research Louisville, Louisville, KY. October 2018
A.E. Geller, H. Guo, C. Ding, J. Yan. “ß-glucan as an anticancer agent in the scope of
trained immunity: future implications for pancreatic cancer.” American Physician
Scientist Association Conference, Chicago, IL. April 2019
A.E. Geller, H. Guo, C. Ding, J. Yan. “ß-glucan as an anticancer agent in the scope of
trained immunity: future implications for pancreatic cancer.” National MD/PhD
Conference, Copper Mountain, CO. July 2019
A.E. Geller, H. Guo, C. Ding, J. Yan. “Harnessing the power of ß- Glucan in trained
immunity, to treat and prevent pancreatic cancer .” Research Louisville, Louisville, KY.
October 2019
A.E. Geller, C Ding, H Guo and JYan. “Harnessing the power of trained immunity using
yeast-derived ß- Glucan in trained immunity to treat and prevent pancreatic cancer.”
Journal of Immunology, May 1 2020. American Association of Immunologists. Vol 204,
Issue 1, Supplement
177

Liang Liu, Anne Geller, Jun Yan and Haixun Guo. “89Zr-labeled anti-Pd-1 antibody for
in vivo monitoring of infiltrating PD-1+ T lymphocytes in a pancreatic tumor mouse
model.” Journal of Nuclear Medicine, Vol 61, Issue supplement 1 May 1, 2020

178

